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Chapter 1
Introduction
Before a drug is allowed into clinical practice, randomized clinical trial (RCT) 
have been conducted in order to demonstrate effi cacy and safety. The RCT 
method uses random treatment allocation to achieve comparable study 
groups and is further characterized by strict patient inclusion criteria, and 
strict follow-up schemes of the study groups.2,3 
Once a drug enters the market, the drug is prescribed to a large number of 
heterogeneous patients who have concomitant diseases and drug use. As a 
result, unknown side effects may emerge (e.g., rare side effects, side effects 
due to interactions or comorbidity). In addition, the effectiveness of the 
drug in clinical practice is not the same as the effi cacy of the drug in clinical 
studies, mostly because usage patterns can be quite different. Postmarketing 
surveillance is the fi eld that studies the benefi cial and negative effects of 
drugs after they have been marketed.
In post-marketing studies, both experimental and observational methods 
can be applied to study drug safety and effectiveness. Both methods have 
advantages and disadvantages. We will fi rst briefl y discuss these methods. 
Experimental Methods
Pragmatic or naturalistic trials are suggested as a possible solution to the 
low generalisability of pre-marketing RCTs. In a pragmatic trial treatment is 
assigned randomly but patient inclusion is more liberal (less strict inclusion 
criteria) and the treatment modalities are not organized as strictly as in RCTs 
(corresponding with regular patient care).5 Therefore the results of pragmatic 
trials show effectiveness rather than effi cacy and better refl ect routine care 
practice. However, pragmatic trials often fail (or are not even considered as 
a possible alternative) because the implementation is time consuming and 
disrupts daily care processes or is ethically diffi cult.6,7
Observational methods
Observational post-marketing studies typically are based on data that are 
collected for other purposes such as claims data or electronic medical records. 
With the advent of electronic medical records, the volume of data available 
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to the researcher has increased; Examples are the general practice research 
data bases that emerged in several countries. Typically, analytic observational 
studies on drug effects in these databases rely on cohort and case-control 
designs. 
Observational databases allow researchers to study large heterogeneous 
populations, various outcomes and treatments applied under daily practice 
circumstances.8 Results from these studies, however, are often the subject of 
criticism due to the absence of randomization.9,10,11 Without randomization, 
there is no guarantee that the treatment groups are comparable for all 
observed and unobserved prognostic factors and the results could therefore 
be subject to confounding by indication. 
Confounding by indication occurs when a treatment is administered based 
on patient factors that are related to the prognosis of the patient or clinical 
endpoints.12 Methods or techniques to rule out this form of bias completely 
in studies based on historic data are lacking. 
Researchers engaged in post-marketing surveillance argued that an ideal 
design should comprise both the strengths of the experimental methods (i.e. 
randomised treatment allocation) and that of the observational methods 
(routine care follow-up provided by general practice databases). The challenge 
to develop a strategy that combines these strengths has resulted in a number 
of appealing research strategies and techniques:
Cross-design synthesis – a strategy of meta-analyses that combines studies 
with different study designs. Conventional meta-analyses combine 
results from complementary RCTs that cover different portion of patient 
populations in order to approximate the total patient population.13 Cross-
design synthesis combines the assessment, adjustment, and combination 
of treatment effects obtained in RCTs and observational studies.14 An 
important drawbacks of cross-design synthesis is that several parts of the 
process require subjective judgments.15 
Randomised database studies – a prospective study in which the Electronic 
Patient Record (EPR) is used to identify eligible cases, randomly assign 
treatment, and record the naturalistic follow-up of the treatment.16 
The outcome is assessed with information that is routinely collected and 
recorded in the EPR. Here, the claim is that randomised database studies 
would facilitate the assessment of drug effectiveness in large populations 
in real life practice by simultaneously using the strengths of experimental 
and observational methods. Although the advantage of this research 
strategy has been recognized, the method has only been described as a 
theoretical possibility – practical experience (e.g., actual implementation) 
is not yet available.
1.
2.
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General practice research database 
In an environment where general practice research databases as data resource 
for observational studies are extensively used, the idea of randomized 
database studies is appealing. These general practice research databases 
are collections of EPRs used in general practices. In countries where general 
practitioners (GPs) have a gatekeeper’s role in the healthcare system, this 
has led to population-based databases. A general practice research database 
typically contains information on patient identifi cation, demographics, 
duration of observation, prescriptions, diagnoses, reason for encounter, 
referrals, laboratory fi ndings and other notes. Well-known general practice 
research databases exist in several European countries, for example in the 
United Kingdom (GPRD and Mediplus), Italy (Health Search and Pedianet), or 
the Netherlands (IPCI and LINH).17 
Integrated Primary Care Database (IPCI)
In the early 1990s, the department of Medical Informatics of the Erasmus 
University Medical Center in Rotterdam initiated the development of a 
general practice research database, the Integrated Primary Care Information 
(IPCI) database. The main objective of the IPCI databases was to achieve 
longitudinal medical information on large populations that can be used 
for post-marketing drug research. The development of the IPCI database is 
described in more details elsewhere.18 
Since the development of the IPCI database, it has been used in many post-
marketing observational studies on a variety of issues ranging from drug safety, 
incidence and prevalence of disease, to drug effectiveness.19-24 Despite the 
successful use of the IPCI database for drug safety studies, studies concerning 
the effectiveness of treatments are diffi cult to conduct due to confounding 
issues. In an attempt to address these limitations, we wanted to explore the 
potential of the randomized database study in the IPCI database.
Objective of the thesis
The main objective of this thesis is to further explore the randomised database 
study and test its feasibility and validity in the IPCI database project.
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As an application, we aimed to compare the gastrointestinal tolerability 
of celecoxib and diclofenac in patients diagnosed with osteoarthritis and 
subsequently treated. 
The fi rst part of this thesis, Chapters 2 through 4, is proof of concept. The 
presence of preferential prescribing (channelling) of selective COX-2 inhibitors 
to a specifi c patient population was demonstrated. In the presence of strong 
channelling it is diffi cult to draw conclusions of a potential increased risk that 
was shown in a study that assessed the association between gastrointestinal 
bleeding or ulcers and use of selective COX-2 inhibitors, it was deemed 
diffi cult to assess the gastrointestinal tolerability of COX-2 inhibitors without 
randomisation. 
In the second part of this thesis, Chapters 5 through 7 we describe the 
exploration, implementation and evaluation of a randomised database study 
(to compare the gastrointestinal tolerability of celecoxib and diclofenac) in 
the IPCI database.
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Abstract
Purpose: To assess use and channelling of COX-2 selective inhibitors (coxibs) 
over time and to estimate the percentage of coxib users with cardiovascular 
contraindications. 
Methods: The study population comprised all coxib and non-selective non-
steroidal anti-infl ammatory drugs (nNSAIDs) users in the Integrated Primary 
Care Information project between the period January 2000 and December 
2004. The prevalence of risk factors for NSAID-related upper gastrointestinal 
ulcer complications, cardiovascular disease, and cerebro-vascular disease at 
the start of treatment was compared between users of coxibs and users of 
nNSAIDs.
Results: The study population included 72,841 users of nNSAIDs and 10,739 
users of coxibs. The baseline prevalence of risk factors for NSAID-related 
gastrointestinal complications was higher in users of coxibs than nNSAIDs 
(OR 1.18, 95% CI 1.10−1.26). Similarly the prevalence of prior cardiovascular 
disease was higher in users of coxibs than in users of nNSAIDs (OR 1.35, 
95% CI 1.28−1.43). Channelling of coxibs to patients with NSAID-related 
gastrointestinal risk factors declined after 2001 but increased again in 2004, 
while the channelling of coxibs to patients with cardiovascular disease 
remained constant. Less than 15% of all coxib users had history of ischemic 
coronary or cerebro-vascular disease. Among coxib users with increased risk 
for NSAID-related gastrointestinal disorders, 27% had history of ischemic 
coronary or cerebro-vascular disease.
Conclusion: This study shows that coxibs were preferentially prescribed to 
patients with risk factors for NSAID-related gastrointestinal disorders and/or 
cardiovascular diseases. Only a quarter of coxib users with increased risk for 
NSAID-related gastrointestinal complications had cardiovascular conditions 
compatible with recent European safety contraindications for coxibs.
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Introduction
Non-selective non-steroidal anti-infl ammatory drugs (nNSAIDs) are commonly 
used in the treatment of arthritis, pain and stiffness, but are associated with 
a 2 to 3 fold increase in the risk of upper gastrointestinal (UGI) complications 
such as bleeding, ulcers and perforation1,2 due to the inhibition of cyclo-
oxygenase (COX)-1. COX-2 selective inhibitors (coxibs) are effi cacious pain 
relievers and reduce the risk of serious gastrointestinal (UGI) complication as 
compared to nNSAIDs.3,4,5
Based on evidence from clinical trials and cost-effectiveness analyses, the 
Dutch General Practice guidelines (2003) (in line with international guidelines), 
recommend that coxibs should be used only in persons with an increased risk 
of NSAID-related GI complications.6,7,8
The cardiovascular safety profi le of rofecoxib has been discussed since the 
VIGOR (VIoxx Gastrointestinal Outcomes Research study) trial was published 
in 2000.3 In 2002, the Food and Drug Administration (FDA) required a change 
in the package insert advising that caution should be exerted when Vioxx 
is used in patients with a medical history of ischemic disease. The drug was 
removed from the market in September 2004 because of cardiovascular 
safety problems.9 In February 2005, the European Medicine Agency (EMEA) 
contraindicated the use of any coxibs in patients with ischemic heart disease 
or stroke, and the use of etoricixb in patients with r hypertension.10 An 
Advisory Committee recommended to the FDA in February 2005 to issue a 
black box warning regarding the risk of heart attack and stroke for all coxibs. 
Due to the discussion about cardiovascular safety, the new contraindications 
and the clustering of GI risk and cardiovascular conditions, physicians may be 
confused to whom to prescribe coxibs. 
Only few studies are available on the use of coxibs in the general population 
and all of them are relate to North-America.11,12 In addition, little or no 
information is available on the concurrent prevalence of NSAID-related GI 
risk and cardiovascular disease in coxib users. 
Evidence of channelling of coxibs to persons with NSAID-related GI risk 
factors is consistently described in all observational studies that aimed to 
study the gastrointestinal and/or cardiovascular effects of coxibs as compared 
to nNSAIDs, both in Canada13 as well as in the USA.13-17 In a UK study on 
GI outcomes, it was shown that coxibs are prescribed to patients with a 
greater disease severity, more co-morbid conditions and higher prevalence 
of gastrointestinal risk factors.18 The concurrent existence of cardiovascular 
disease risk and GI disease risk was not described.
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In view of the limited information on use and channelling of coxibs in Europe, 
the recent safety restrictions and the current confusion among physicians to 
whom to prescribe coxibs we aimed to describe the extent of coxib use in the 
fi rst 5 years of marketing, to assess patterns of channelling of coxibs between 
2000 and 2004, and to assess the percentage of coxib users with and without 
concurrent risk factors for NSAID-related GI complications and cardiovascular 
disease. 
Methods
Setting 
We conducted a population-based study in the Integrated Primary Care 
Information (IPCI) database. The IPCI database is a general practice research 
database in the Netherlands that comprises the complete electronic medical 
records of more than 500,000 patients. Details of the database have been 
published elsewhere.19 In brief, the database contains anonymous data on 
patients’ demographics, signs and symptoms, physical evaluation and fi ndings, 
diagnoses, prescriptions, referrals, laboratory examinations and summaries of 
discharge letters. There is a complete record of all drug prescriptions, their 
indication, and dosage regimen. To maximize completeness of the data, GPs 
participating in the IPCI project are not allowed to maintain a system of 
paper-based records besides the electronic medical records. The IPCI system 
complies with the European Union guideline on the use of medical data for 
research and has been proven valid for pharmaco-epidemiological research.19 
The Scientifi c and Ethical Advisory Board of the IPCI project approved this 
study.
The source population for description of drug use comprised all subjects 
registered in the IPCI database during the study period (January 
2000−December 2004). Each subject was followed from registration with the 
GP or start of the study period until the earliest of death, transferring out, 
or end of study period. The population for assessment of channeling and 
prevalence of concurrent risk factors for NSAID-related GI complications and 
cardiovascular disease comprised all persons with at least 12 months of valid 
database history. 
Drug use was categorized in use of non-selective NSAIDs (all M01A except 
for COX-2 preferential drugs and COX-2 selective drugs) and use of coxibs 
(rofecoxib, celecoxib, etoricoxib, valdecoxib). In the assessment of channeling, 
the diclofenac+misoprostol (in a fi xed combination) and COX-2 preferential 
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drugs (meloxicam, nabumetone) were excluded from the non-selective NSAIDs 
class.
Patient characteristics
The fi rst time a person had an nNSAID or coxib prescription during the study 
period we assessed age, gender and the prevalence or history of the following 
diseases and conditions 12 months prior to the prescription: gastrointestinal 
co-morbidity (peptic ulcer disease, gastrointestinal hemorrhage, gastritis, 
duodenitis, dyspepsia and abdominal pain), cardiovascular co-morbidity 
(ischemic heart disease, chronic heart failure, hypertension, hyperlipidemia), 
stroke, and diabetes mellitus. Prior use of systemic corticosteroids, antiacids, 
Histamine2 (H2)-receptor antagonists, proton pump inhibitors (PPIs), other 
ulcer healing drugs, and cardiovascular drugs (positive inotropics, diuretics, 
ß-blockers, angiotensin-converting enzyme (ACE) inhibitors plus angiotensin 
II receptor blockers, vasodilators, anticoagulants, lipid-lowering drugs) issued 
in the 6-months period prior to the prescription of the nNSAID or coxib.
As overall measure of NSAID-related GI risk, the cumulative number 
of generally recognized risk factors for NSAID-related upper GI ulcer 
complications was calculated (age >65 years, use of systemic corticosteroids, 
use of anticoagulants or acetylsalicylic acid, and a history of peptic ulcer or 
gastrointestinal bleeding). 
Patients were considered to have cardiovascular disease (contraindications) if 
they had a history of stroke, heart failure or ischemic heart disease.
Statistical analysis
Use of nNSAIDs and coxibs was described in terms of users per 1000 person-
years of follow-up. 
Logistic regression was used for assessment of channeling; in these analyses 
the odds of patient characteristics were separately compared between users 
of coxibs and users of nNSAIDs, while adjusting for age and gender. Therefore 
the observational unit in the logistic regression was a prescription of either a 
coxib (outcome 1) or an nNSAID (outcome 0). About 8% of the prescriptions 
were re-prescriptions in the same patient. The dependence of prescriptions 
within the same patient was accounted for by using earlier use of a coxib 
or nNSAID as predictor variable in the logistic regression. To look at patient 
characteristics as determinant for use of coxibs while adjusting for prescribing 
preference within a GP practice, in addition to age and gender, we used 
logistic regression with practice as a random effect, using PROC NLMIXED 
in SAS. Calendar year stratifi ed analyses were conducted to verify trends 
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in channeling over time. All analyses were performed with SPSS version 11 
(Chicago, IL) and SAS Release 8.2 (version 8.2 Cary, North Carolina). 
Results
In the source population of more than 470,000 subjects during 2000–2004, 
use of non-selective NSAIDs decreased from 161 to 131 users per 1000 person 
years between 2000 and 2004. Meanwhile, use of coxibs increased from 0 to 
32 users per 1000 person years (Figure 1). 
Figure 1: Use of non-selective NSAIDs (upper) and coxibs (lower) between 2000 and 2004. 
The X-axis represent the year of observation and the Y-axis represent the number of NSAID 
users per 1000 persons years of observation. 
The subpopulation for assessment of channelling comprised 77,177 
patients. Non-selective NSAIDs were used by 72,841 persons, and coxibs by 
10,739. 6,403 patients had more than one prescription for a study drug and 
therefore entered more than once in the study. The mean percentage of 
coxib prescriptions over the total number of NSAIDs per practice increased 
from 6% in 2000 to 28% in 2004; 10% of the practices never prescribed 
coxibs during the study period. 
Patients starting coxibs were more likely to be female (65.7% versus 56.8%) 
and older than those starting non-selective NSAIDs (mean ± SD, 58.3±17.0 
years versus 46.1±17.7 years) (Table 1). Coxib users also had received NSAIDs 
(31.5 % versus 10.7%) and acid suppressive drugs (16.6% versus 6.8%) more 
frequently than non-selective NSAID users in the 6 months prior (Table 1). 
Use of cardiovascular drugs was 2.5 fold higher in coxib than nNSAID users. 
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The differences in prior or concomitant drug diminished substantially after 
adjustment for age, gender, and practice, but remained statistically different 
(Table 1). In line with the observed differences in drug use, the prevalence/
history of gastrointestinal, cardiovascular, cerebro-vascular diseases, and 
diabetes mellitus, were all higher in coxib users than in NSAID users (Table 1). 
Patients with ischemic heart disease or history of stroke were 32% and 23% 
more likely to receive a coxib, respectively. The most important determinants 
for prescription of a coxib were use of NSAIDs in the 6 months prior (OR 3.23, 
95% CI 3.07−3.41), use of acid suppressive drugs (OR 2.01, 95% CI 1.89−2.15) 
and a history of GI disorders (OR 1.82, 95% CI 1.72−1.92). 
Aggregation of risk factors showed that an increasing number of risk factors 
for NSAID-related GI complications increased the probability of receiving a 
coxib (Table 1). The extent of channelling of coxibs related to risk factors 
for NSAID-related GI complications decreased from being 40% more likely 
to receive a coxib if at least one GI risk factor was present to no increased 
probability in 2003 (Figure 2). Patients with cardiovascular disease were 20% 
to 30% more likely to receive a coxib than patients without cardiovascular 
disease, and this pattern did not change over time (Figure 3). In absence of 
gastrointestinal disease, cardiovascular disease remained an independent risk 
factor for receiving coxibs (Table 1). 
Figure 2: Probability of receiving coxibs for persons with at least one risk factor for NSAID-
related gastrointestinal complications compared to patient without these risk factors (odds 
ratio adjusted for practice, age and gender). The X-axis represent the year of observation 
and the Y-axis represent the odds ratio. 
About 45% of coxib users had one or more baseline risk factors for NSAID-
related upper gastrointestinal complications, while these were present in 
20.2 % of nNSAIDs users. Overall, less than 15% of coxib users would have 
had a cardiovascular contraindication, when we applied the February 
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2005 safety restrictions to the study period. Among the persons with at 
least one risk factor for NSAID-related GI complications, 27% had also a 
contraindicated cardiovascular condition. 
Figure 3: Probability of receiving coxibs for persons with cardiovascular disease compared 
to patients without cardiovascular disease (Odds Ratio adjusted for practice, age and 
gender). The X-axis represents the year of observation and the Y-axis represent the odds 
ratio. 
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Discussion
This study showed that coxib use gradually increased at the expense of non-
selective NSAID use during the fi rst 5 years of marketing in the Netherlands. 
In line with the diffusion of coxib use, channelling related to the presence of 
a risk factor for NSAID-related GI complications decreased until 2004. 
We estimated that 85% of all coxib users and 75% of persons with increased 
risk of NSAID-related GI complications have no history of contra-indicated 
cardiovascular disease and would be remain eligible for a coxib prescription. 
In view of the debates about the cardiovascular safety of coxibs, it is note-
worthy that persons with cardiovascular disease (even in absence of GI risk) 
were more likely to receive a coxib.20 Also, despite channelling to persons 
with GI risk factors, most coxib users are persons without risk factors for 
NSAID-related GI disorders. Our fi ndings are in line with studies in the UK and 
USA, which have shown that coxibs are mostly prescribed to persons without 
increased risk of NSAID-related GI disorders.18,21
Our data on channelling of coxibs are in line with group differences in 
observational studies that compared gastrointestinal or cardiovascular 
safety between coxibs and NSAIDs.13-18 Solomon and MacDonald showed 
that coxib users in the US and in UK also had a higher prevalence of GI risk 
factors.18,21 Cohort studies (US and Canada) that compared cardiovascular 
outcomes between coxibs and nNSAIDs showed that coxib users had more 
cardiovascular co-medication and co-morbidity, higher prior use of NSAIDs, 
and more prescriptions at baseline,13-17 which is in line with our data.
The differences between the population average and the practice adjusted 
odds ratios indicate that some, but not all of the observed overall channelling 
is due to patient characteristics. This observation is consistent with studies in 
Medicare21,22 showing that fi rst time selective COX-2 inhibitor prescribing is 
dependent on both gastrointestinal risk factors and physicians’ preference 
in the fi rst 2 years of the availability. Our data also showed an impact of 
physicians’ preference in relation to the other determinants, although the 
impact was less substantial in the period of 5 years of observation.
Our study has some limitations that should be considered when reviewing 
the results. First, we conducted a cohort study in which a patient could 
contribute multiple times to the study cohort if he/she uses different NSAIDs 
during the study period. The number of persons entering twice was around 
8%. Sensitivity analyses in which patients were included only once only had 
a minor effect on the results and did not change the conclusion. Second, the 
IPCI database did not contain enough coxibs users to enable us to analyse 
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individual coxibs. As a result, we combined the individual coxibs into one 
group. Lastly, there could be dependency in the data regarding general 
practices that preferentially prescribe a certain NSAID. Even though we 
attempt to adjust for this phenomenon with non-linear mixed model, it is no 
guarantee that the results are partly because of residual confounding.
In conclusion, this study showed that the use of coxibs have increased 
substantially between 2000 and 2004. The baseline prevalence of these factors 
was about 50% among users of coxibs and 20% among users of nNSAIDs. Only 
a quarter of coxib users with increased risk for NSAID-related GI complications 
had cardiovascular conditions compatible with recent European safety 
contraindications for coxibs.
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NSAIDs and the risk of ulcers and 
upper gastrointestinal bleeding: 
A nested case-control study
30
Chapter 3
Abstract
Objective: To compare the gastro-intestinal safety between selective 
COX-2 inhibitors (coxibs) and the one pill combination of diclofenac and 
misoprostol 
Methods: Within the Integrated Primary Care Information (IPCI) general 
practice database, we conducted a nested case control study in a cohort of 
new NSAIDs users, 65 years and older, in the period between November 1999 
and December 2004. Cases were all persons with a validated diagnosis of an 
upper gastrointestinal (GI) bleeding or a peptic ulcer, and at least one year 
of valid history prior to cohort entry. Each case was matched on calendar 
time, age, and gender to all available controls at the date of the GI event. 
The risk of GI bleeding or peptic ulcer among current users of coxibs was 
compared to that of current users of the one pill combination of diclofenac 
and misoprostol.
Results: We identifi ed 217 cases of gastrointestinal bleedings and peptic ulcers 
during the study period. We observed an increased risk of gastrointestinal 
bleeding and ulcers for current use of coxibs (OR 2.92, 95%CI: 1.11−7.65) as 
compared to the one pill combination of diclofenac and misoprostol. 
Conclusion: Our data show that the risk of gastrointestinal ulcers and 
bleedings is increased during use of coxibs compared to use of the one-pill 
combination of diclofenac and misoprostol. 
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Introduction
Data from two landmark clinical trials in patients with rheumatological 
disease have demonstrated that COX-2 selective inhibitors (coxibs) reduce 
the risk of gastrointestinal bleedings and ulcers as compared to non-selective 
non-steroidal anti-infl ammatory drugs (nNSAIDs).1,2 Other randomised 
studies have confi rmed these fi ndings.3-5 Based on cost-effectiveness analyses, 
international guidelines recommend the use of coxibs in persons at increased 
risk of NSAID-related complications6-8 and as a result coxibs are channelled to 
this population.9,10 
An alternative treatment strategy to reduce the risk of NSAID-related 
gastrointestinal complication is the use NSAID with gastro-protective agents 
such as misoprostol, proton pump inhibitors, and histamine-2 (H2)-receptor 
antagonists. 
Evidence from a randomised clinical trial showed that celecoxib was not 
inferior to diclofenac in combination with omeprazole regarding recurrent 
ulcer bleedings in patients at high risk of this condition.11 Other randomized 
studies on the comparison between coxibs and non-selective NSAIDs with 
gastro-protective agents are not available as far as we know. Several 
observational studies data compared the gastrointestinal safety of coxibs and 
non-selective NSAIDs10,12-14 but no studies have directly compared coxibs to 
the one pill combination of diclofenac and misoprostol.
The objective of this nested case-control study was to investigate whether 
the risk of upper gastro-intestinal bleedings and peptic ulcers is comparable 
between use of coxibs and use of diclofenac plus misoprostol in a population 
that is eligible for gastro-protection during use of NSAIDs. 
Methods
Setting
This study was conducted in the Integrated Primary Care Information (IPCI) 
database. The IPCI database has been described elsewhere.15 In brief, IPCI is 
a longitudinal general practice research database that contains data from 
computer-based patient records of a selected group of general practitioners 
(GPs) throughout the Netherlands. As of December 2004 there are more than 
150 GPs who have provided data to the database. The database contains 
information on about 500,000 patients with an age and gender distribution 
comparable to the Dutch population. The database contains anonymized 
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plus demographic information (age, sex, GP registration information), notes, 
prescriptions, physician-linked indications for therapy, physical fi ndings, and 
laboratory values which are directly entered into the computer by the GP. 
The International Classifi cation of Primary Care (ICPC) is the coding system 
for patient complaints and diagnoses, but diagnoses and complaints can also 
be entered as free text. Prescription data such as product name, quantity 
dispensed, dosage regimens, strength, indication and Anatomical Therapeutic 
Chemical (ATC) codes are entered directly into the computer by the GPs. The 
system complies with European Union guidelines on the use of medical data 
for medical research and has been proven valid for pharmaco-epidemiological 
research.15 The Scientifi c Advisory Board of the IPCI database approved this 
study.
Study population
A nested case control study was conducted in a cohort of new NSAID users 
who were 65 years or older during the period November 1999 and December 
2004. All subjects were followed from the fi rst NSAID prescription, until the 
end of the study period, death or occurrence of the outcome, whichever came 
fi rst.
Once entered in the study cohort, patients could contribute to multiple 
episodes of NSAID use, if they switched or restarted therapy. NSAIDs were 
categorized in non-selective NSAIDs, the one pill combination of diclofenac 
and misoprostol, and coxibs. Contribution to an exposure category ended 
at the end of the prescription, or at the start of a new NSAID of a different 
category, or at the occurrence of a study outcome (whichever was earliest). 
When two or more NSAIDs categories overlapped, they were assigned to a 
combination category.
Case defi nition
The primary outcome was defi ned as an upper GI bleeding or a symptomatic 
peptic ulcer. All potential cases were manually validated by two medical 
doctors to exclude false positive records and to assess the earliest date of 
onset of each of the events (index date). Cases were classifi ed as defi nite or 
possible cases based on the availability of endoscopic conformation. At the 
date of case occurrence we sampled all available controls who were in the 
cohort and who could be matched to the case on age (year of birth), year of 
fi rst NSAID use during the study period, gender, and index date. 
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Exposure defi nition
From the prescription records we obtained all prescriptions for NSAIDs and 
classifi ed exposure prior to the index date in mutually exclusive groups of 
current (still using or stopped 30 days before), past (stopped 31−180 days 
before the index date) and remote use (stopped more than 180 days prior 
to the index date). Groups were made for non-selective NSAIDs (nNSAIDs) 
(diclofenac, ibuprofen, naproxen and others), the one pill combination of 
diclofenac and misoprostol (Arthrotec) and coxibs (rofecoxib, celecoxib, 
etericoxib and other coxibs). 
Co-variates
We considered the following conditions as potential confounders for the 
association between upper GI bleeding and peptic ulcers and the use of 
NSAIDs: smoking, prior ischemic cardiovascular events (angina, myocardial 
infarction, stroke), hypertension, diabetes mellitus, heart failure, prior 
gastrointestinal events (perforation, ulcers or bleedings), prior gastritis or 
duodenitis and the indication for NSAID use (osteoarthritis, rheumatoid 
arthritis, other musculoskeletal disorders, pain, or other indications).
Concomitant drug use was assessed up to one week prior to the index date 
to avoid protophathic bias and included: cardiovascular drug use (diuretics, 
digoxin, ACE inhibitors, calcium channel blockers (CCB), Beta-blockers and 
lipid lowering drugs), aspirin, systemic corticosteroids, selective serotonin 
reuptake inhibitors (SSRI), antibiotics, estrogens, gastro-protective drugs 
(proton pump inhibitors (PPIs), Histamine (H)2-receptor antagonists), antacids 
and anti-thrombotic agents.
 
Statistical Analysis
The association between GI bleedings and peptic ulcers and the co-variates 
was assessed through conditional logistic regression analysis. All covariates 
that were associated with the outcome (p<0.05) were considered as potential 
confounders and were used in the multivariate regression models.
For the principal analyses we compared current use of coxibs with current use 
of the one pill combination of diclofenac and misoprostol. Several sensitivity 
analyses were conducted by varying the reference group to remote use of 
NSAIDs, or use of NSAID plus PPIs and by restriction of the analyses to defi nite 
cases of gastrointestinal bleedings and ulcers. All analyses were conducted by 
using SPSS version 11 (Chicago, IL).
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Results
A total of 27321 persons contributed to 1594 person-years of current coxib 
use, 6515 person-years of nNSAID use and 907 person-years of diclofenac plus 
misoprostol use. 
In the study cohort we observed 217 cases of upper GI bleeding and peptic ulcers 
after entry. Compared to the controls, cases more frequently used diuretics 
(OR 1.76, 95%CI 1.28−2.44), ACE inhibitors (OR 1.69, 95%CI 1.18−2.43), SSRIs 
(OR 2.38 95%CI 1.19−4.78), antibiotics (OR 3.59 95%CI 1.82−7.06), and anti-
thrombotic agents (OR 2.32 95%CI 1.66−3.23). Cases also more often were 
smokers, more often had chronic obstructive lung disease, cardiovascular co-
morbidity, and more frequently had a history of gastrointestinal events (Table 
1). To evaluate the association between covariates and exposure we looked 
at this association among the controls. Current coxib users more often had 
a history of stroke, gastritis and duodenitis, and hypertension compared to 
users of the one pill combination of diclofenac and misoprostol. Coxib users 
also more frequently used PPIs (Table 2).
In the primary analyses, none of the potential confounding factors infl uenced 
the point estimate between current use of coxibs and the one pill combination 
of diclofenac and misoprostol. Current use of coxibs was associated with 
a 2.9 fold increased risk of GI bleedings and peptic ulcers (OR 2.92 95%CI 
1.11−7.65) as compared to use of the one pill combination of diclofenac and 
misoprostol. The risk was even higher in the group of patients who used both 
a non-selective NSAIDs and a coxib (OR 8.4 95%CI 2.0−35.1) (Table 3).
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Table 1: Characteristics of cases and controls and association with ulcers and GI bleeding. 
Controls 
(n=9862)
Cases 
(n=217)
OR 95%CI
Males 2771 28.1 80 36.9 − –
Age (mean, sd) 74.9 (6.0) 78.3 (7.6)
Smokers 1918 20.2% 56 25.8% 1.71 1.24 2.36
Chronic obstructive lung disease 1023 10.4% 33 15.2% 1.57 1.07 2.31
Diabetes Mellitus 1240 12.6% 31 14.3% 1.11 0.75 1.65
History of Perforation ulcers and 
bleedings
360 3.7% 13 6.0% 1.56 0.88 2.80
History gastritis/duodenitis 1898 19.2% 51 23.5% 1.39 1.00 1.93
Cardiovascular events
Angina 1217 12.3% 44 20.3% 1.70 1.20 2.41
History of myocardial infarction 545 5.5% 12 50.5% 0.93 0.51 1.69
History of Stroke 725 7.4% 30 13.8% 1.54 1.02 2.34
Hypertension 3762 38.1% 79 36.4% 0.97 0.73 1.29
Peripheral arterial disease 491 5.0% 24 11.1% 2.17 1.83 3.39
Arrhythmia 675 6.8% 29 13.4% 1.73 1.14 2.61
Heart failure 680 6.9% 28 12.9% 1.40 0.92 2.15
Indication
Arthritis 873 8.9% 22 10.1% ref ref ref
Rheumatoid arthritis 132 1.3% 3 1.4% 0.91 0.26 3.16
Other musculoskeletal disorders 4871 49.4% 83 38.2% 0.74 0.45 1.20
Other indications 1090 11.1% 35 16.1% 1.35 0.77 2.36
Not recorded 2896 29.4% 74 34.1% 1.10 0.67 1.81
Cardiovascular drugs
Diuretics 1564 15.9% 58 26.7% 1.76 1.28 2.44
Digoxin 242 2.5% 13 6.0% 1.83 0.998 3.37
ACE-I 1091 11.1% 39 18.0% 1.69 1.18 2.43
CCBs 894 9.1% 27 12.4% 1.35 0.89 2.06
B-Blockers 1598 16.2% 41 18.9% 1.20 0.84 1.71
Lipid lowering drugs 929 9.4% 21 9.7% 1.29 0.81 2.06
Aspirin 786 8.0% 27 12.4% 1.50 0.98 2.27
Corticosteroids 200 2.0% 6 2.8% 1.13 0.48 2.71
SSRIs 193 2.0% 9 4.1% 2.38 1.19 4.78
Antibiotics 141 1.4% 10 4.6% 3.59 1.82 7.06
Proton pump inhibitors 714 7.2% 17 7.8% 1.13 0.68 1.87
H2 receptor antagonist 286 2.9% 7 3.2% 1.11 0.51 2.41
Anti-thrombotic agents 1066 10.8% 51 23.5% 2.32 1.66 3.23
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Table 2: Characteristics of the controls currently exposed to coxibs and NSAIDs.
Current Coxib 
(n=325)
Current diclofenac
+misoprostol
(n=231)
Current nNSAID
(n=1260)
n % n % n %
Gender (male %) 53** 16.3 50* 21.6 354 28.1
Smokers 66 20.3 36 15.6 210 16.7
Chronic obstructive lung disease 32 9.8 33* 14.3 119 9.4
Diabetes Mellitus 43 13.2 27 11.7 166 13.2
History of perforation ulcer 
bleedings
13 4.0 11 4.8 35 2.8
History of gastritis or duodenitis 72* 10.2 51* 22.1 203 16.1
Cardio vascular events
Angina 42 12.9 24 10.4 142 11.3
History of myocardial infarction 18 5.5 12 5.2 57 4.5
History of stroke 39* 12.0 14 6.1 99 7.9
Hypertension 156** 48.0 91 39.4 476 37.8
Peripheral arterial disease 7 2.2 11 4.8 51 4.0
Arrhythmia 26 8.0 15 6.5 70 5.6
Heart failure 33 6.9 22 9.5 100 7.9
Indication
Arthritis 53 16.3 26 11.3 154 12.2
Rheumatoid arthritis 10 3.1 8 3.5 27 2.1
Other musculoskeletal disorders 137 42.2 104 45.0 541 42.9
Other pain 33 10.2 30 13.0 109 8.7
Other indications 92 28.3 63 27.3 429 34.0
Cardiovascular drugs
Diuretics 68 20.9 41 17.7 245 19.4
Digoxin 6 1.8 3 1.3 31 2.5
ACE inhibitors 48 14.8 34 14.7 160 12.7
CCB 40 12.3 25 10.8 137 10.9
Beta-Blockers 47 14.5 35 15.2 218 17.3
Lipid lowering drugs 26 8.0 20 8.7 111 8.8
Aspirin 30 9.2 19 8.2 117 9.3
Corticosteroids 13 4.0 12* 5.2 27 2.1
SSRI 5 1.5 7 3.0 25 2.0
Antibiotics 2 0.6 3 1.3 24 1.9
Gastro-protective agents
PPI 42* 12.9 23 10.0 111 8.8
H2 receptor antagonist 18 5.5 10 4.3 46 3.7
Antiacids 4 1.2 2 0.9 9 0.7
* p<0.05, ** p<0.001 – Current diclofenac+misoprostol as reference group.
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Table 3: Risk of gastrointestinal bleeding and ulcers with current, past and remote use of 
nNSAID, coxibs an combinations of coxibs and nNSAID.
Case
(n=217)
Control
(n=9862)
OR crude 95.0% CI 
Current diclofenac 
+misoprostol
  6 (2.8%)  231 (2.3%) Ref.
Current coxib  22 (10.1%)  325 (3.3%) 2.92 1.11 7.65
Current NSAID  54 (24.9%) 1260 (65.8%) 1.95 0.81 4.66
Current coxib + NSAID   4 (1.8%)   20 (0.2%) 8.4 2.0 35.1
Past coxib   4 (1.8%)  252 (2.6%) 0.8 0.2 2.9
Past NSAID  20 (9.2%) 1256 (12.7%) 0.77 0.29 2.01
Past coxib + NSAID   0   26 (0.3%) – – –
Remote use NSAID 107 (49.3%) 6492 (65.8%) 0.83 0.34 2.01
Compared to the one pill combination in normal dosages we observed 
a positive dose response for the association between coxibs and upper GI 
bleeding or ulcers. Use of coxibs in dosages less than twice the defi ned daily 
dose the odds ration was 3.64 95%CI 1.02–13.05, and in current coxibs users 
with dosages more than 2 DDDs the odds ratio was 6.7 95%CI 1.6–28.2. The 
risk of gastrointestinal bleeding and ulcers was also increased in current 
NSAID users with a DDD greater than 2 (ORadj 7.96 95%CI 2.28–27.75) and in 
users of a combination of coxibs and NSAIDs (Table 4). In these analyses we 
adjusted for rhythm disturbances and the use of anti-thrombotic agents.
Table 4: Effect of defi ned daily dosage (DDD) equivalent on gastrointestinal bleedings and 
ulcers.
Cases
(n=217)
Controls
(n=9862)
OR 
crude
ORadj* 95% CI
Current diclofenac+ 
misoprostol <= 2 DDD
  3 (1.4%)  194 (2.0%) Ref. Ref.
Current diclofenac+ 
misoprostol >2 DDD
  3 (1.4%)   37 (0.4%)  5.0 4.9 0.9 26.3
Current coxibs <=2 (DDD)  16 (7.4%)  259 (2.6%)  3.9 3.64 1.02 13.05
Current coxibs >2 (DDD)   6 (2.8%)   66 (0.7%)  7.3 6.7 1.6 28.2
Current nNSAID<=2 (DDD  35 (16.1%) 1102 (11.2%)  2.32 2.30 0.69  7.60
Current nNSAID >2 (DDD)  19 (8.8%)  158 (1.6%)  8.11 7.96 2.28 27.75
Current coxibs+ NSAID   4 (1.8%)   20 (0.2%) 13.0 13.9 2.7 71.2
Past or remote use of any 
NSAID or coxib
131 (60.4%)- 8026 (81.4%)  1.26 1.23 0.38  3.98
*Adjusted for rhythm disturbances and use of anti-thrombotic agents.
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Analyses focused to assess whether concomitant use of PPIs or H2-receptor 
antagonists showed that the increased risk of GI bleeding and peptic ulcers 
in current users of coxibs was restricted to those who did not use gastro-
protective agents (OR 3.00 95%CI 1.13–7.07) (Table 5).
Restriction of the cases to the defi nite cases (n=129) increased the 
association between current use of coxibs and the occurrence of upper 
gastro-intestinal events (OR 5.73, 95% CI 1.53–21.46). 
Table 5: Risks of gastrointestinal bleeding and ulcers in current use of coxibs and nNSAID in 
combination with proton pomp inhibitors (PPI) or H2 receptor antagonist (H2RA)
Cases
(n=217)
Controls
(n=9862)
OR-
crude*
95.0% CI 
Current diclofenac+misoprostol   6 (2.8%)  231 (2.3%) Ref.
Current coxib + PPI and/or H2RA   3 (1.4%)   59 (0.6%) 2.4 0.6 10.2
Current coxib without PPI and H2RA  19 (8.8%)  266 (2.7%) 3.00 1.13 7.97
Current NSAID + PPI and/or H2RA   3 (1.4%)  155 (1.6%) 0.969 0.2 4.0
Current NSAID without PPI and H2RA  51 (23.5%) 1105 (11.2%) 2.08 0.87 5.00
Current coxib + NSAID   4 (1.38%)   20 (0.2%) 8.30 2.0 34.7
Past or remote use of any NSAID or coxib 131 (60.4%) 8026 (81.4%) 0.81 0.34 1.92
* No confounding factors.
Discussion
Our data show evidence that the risk of gastrointestinal bleeding and ulcers is 
higher during current use of coxibs as compared to current use of the one pill 
combination of diclofenac and misoprostol. We also observed a dose response 
relation both for coxibs users as well as for nNSAID use. Among the current 
coxibs users we observed an increased risk of gastrointestinal bleeding and 
ulcer only in those who did not concomitantly use gastro-protective agents.
Other observational studies suggested a protective effect for gastrointestinal 
disorders in coxib users compared to non-selective NSAIDs.12-14,6 Layton et 
al. found a relative reduction (29%) in the incidence rate of symptomatic 
GI events, and no difference in the incidence rate of upper GI conditions 
(perforations/bleeding) for rofecoxib and celecoxib compared with 
meloxicam.12,13 Goldstein et al. concluded that celecoxib use is associated with 
a signifi cantly decreased risk of upper GI symptoms compared to nNSAIDs 
use.14 Mamdani et al. compared patients aged 66 years and older who started 
taking nNSAIDs, diclofenac plus misoprostol, rofecoxib or celecoxib with a 
randomly selected control cohort not exposed to NSAIDs and found a lower 
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short term risk of upper GI bleeding for coxibs.16 Relative to celecoxib, this 
study showed signifi cantly higher risks of upper gastrointestinal bleeding for 
non-selective NSAIDs (4.4 (2.3 to 8.5)), diclofenac plus misoprostol (3.2 (1.6 to 
6.5)), and rofecoxib (1.9 (1.2 to 2.8)).
These studies, however, demonstrated selective prescribing of coxibs to 
patients with greater disease severity, more co-morbid conditions and higher 
prevalence of gastrointestinal risk factors. Such channelling effects may easily 
confound the comparison of gastrointestinal safety of coxibs in naturalistic 
settings.17,18 
Our observation may also be confounded due to unrecognised risks, such 
as incomplete medical history information, undetected or underreported 
risk factors. The physicians’ preference for coxibs could also be an important 
factor to whether a patient is treated with a coxibs or an NSAID (plus a gastro-
protective drug).19,20 We assumed that this channelling phenomenon would 
be less apparent if we compared coxibs use with the alternative treatment 
option of NSAID with a gastro-protective agent. Still, we observed that 
patients treated with coxibs had greater disease severity, more co-morbid 
conditions and higher prevalence of gastrointestinal risk factors compared to 
the one pill combination of diclofenac and misoprostol (Table 1). Our study 
may have suffered from other additional limitations. The exposure to NSAIDs 
was assessed based on prescription records and we could not adjust for use 
of over the counter NSAID. This misclassifi cation could be differential since 
we observed an increased risk and NSAIDs that are available over-the-counter 
increase the risk of gastrointestinal disorders.
We studied gastrointestinal bleeding and ulcers in a population of 27321 
patients, but unfortunately, due to low numbers, we were not able to study 
the different coxibs separately and could not provide any information on the 
gastro-intestinal safety profi le of the different coxibs.
Based on our results and in view of the new knowledge on the potential of 
cardiovascular side effects in users of coxibs, we would suggest that the one 
pill combination of diclofenac and misoprostol should be considered as the 
drug of fi rst choice, especially in high risk patients. 
In conclusion, our data show that the risk of gastrointestinal ulcers and 
bleedings is increased in current users of coxibs compared to diclofenac plus 
misoprostol. The increased risk reduces if coxibs are combined with proton 
pump inhibitors 
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A pilot study to estimate the sample 
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Background
Celecoxib (a selective COX-2 inhibitor) and diclofenac (a non-selective 
NSAID) are offi cially licensed for the treatment of osteoarthritis.1 Due to 
the channeling of selective COX-2 inhibitors to patients with a history of 
gastrointestinal and cardiovascular risk factors,2 it is diffi cult to compare 
gastrointestinal tolerability of these NSAIDs without randomization. 
We therefore aimed to assess gastrointestinal tolerability of celecoxib and 
diclofenac in daily practice with the randomised database study design.3 
Before we conducted the randomised database study, we assessed the 
frequency of the primary study outcome, treatment discontinuation due to 
gastrointestinal intolerability, in a retrospective cohort study with data from 
the Integrated Primary Care Information (IPCI) database. We hereby applied 
patient selection criteria and conducted follow-up as we planned to do in 
the RDS. The aim of pilot study was to assess the number of eligible subjects 
and occurrence of gastrointestinal intolerability during use of diclofenac, to 
better estimate the sample size required for the RDS.
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Methods
Source population
The source population comprised all patients who are registered with one 
of the general practitioners (GPs) who contribute information to the IPCI 
database in the Netherlands. IPCI is a longitudinal observational database 
that contains data from EPRs of a selected group of GPs throughout the 
Netherlands.4 Collaborating practices are comparable to other GPs regarding 
age and gender. Practices have been supplying data for varying periods of 
time and the current IPCI database contains information on over 500,000 
patients. 
The IPCI database contains identifi cation information (age, sex, patient 
identifi cation, GP registration information), notes, prescriptions, indications 
for therapy, physical fi ndings, and laboratory values which are directly entered 
into the computer by the GP. Downloads are made on a monthly basis and 
the information is sent to the gatekeeper who anonymized all information 
before further access is provided. The International Classifi cation of Primary 
Care (ICPC) is the coding system for patient complaints and diagnoses, but 
diagnoses and complaints can also be entered as free text. Prescription data 
such as product name, quantity dispensed, dosage regimens, strength, and 
indication are entered into the computer. The National Database of drugs, 
maintained by the Royal Dutch Association for the Advancement of Pharmacy, 
enables the coding of prescriptions, according to the Anatomical Therapeutic 
Chemical (ATC) classifi cation scheme recommended by the WHO. The system 
complies with European Union guidelines on the use of medical data for 
medical research and has been proven valid for pharmaco-epidemiological 
research.5-9 
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Study population 
Patient selection for the pilot study was in line with that proposed for the RDS. 
In the RDS, special designed software is installed in the information system 
of the participating GPs. At installation of the software, a selection module 
identifi ed all potential eligible patients by means of an automated search 
in the historic medical data. Since the pre-selection of possible candidates 
occurred at one moment in time, we acted as if the module was installed 
on January 1st 2000 in the IPCI database. Patients were pre-selected if they: 
were registered for at least 6 months with their GP, were at least 18 years of 
age, and had a diagnosis of osteoarthritis. The diagnosis of osteoarthritis was 
searched through coded diagnoses (ICPC codes: L84, L89, L90, L91) and text 
strings including ‘osteoarthritis’, ‘joint’ and ‘pain’. The text string selections 
were manually validated to reduce false positively selected patients. 
In the population of pre-selected patients (study population), we identifi ed 
the fi rst NSAID prescription and the fi rst diclofenac prescription during the 
study period (January 2000 to December 2002). The date of the fi rst NSAID 
prescription was considered the index date.
Exclusion criteria
At the index date we assessed the frequency of the following exclusion criteria: 
current treatment with NSAIDs (prescription in the last three months), current 
treatment with a gastro-protective agent (proton pump inhibitors (PPIs), 
Histamine (H)2-recepter antagonists or misoprostol), or contra-indication.
Patients were followed from the index date for a maximum of 6 and 12 
months. Follow-up was censored upon the earliest of the following dates: 
end of NSAID treatment; death; pregnancy; occurrence of study outcome; 
transferring out of the practice.
Primary outcome
The primary outcome was defi ned as gastrointestinal intolerability leading to 
at least one of the following measures: switching to any other type of NSAID/
selective COX-2 inhibitor because of gastro-intestinal complaints; stopping 
of NSAID treatment because of gastro-intestinal complaints; endoscopy, or 
Helicobacter Pylori investigation; addition of gastro-protective drug (proton 
pump inhibitors (PPI), H2-receptor antagonist or misoprostol).
Patients were considered to have stopped if there was a gap of at least 6 
months without a repeat prescription. All EPRs were evaluated to classify 
switching on termination of NSAID treatment, referrals for endoscopy or 
starting with gastro-protective medication as being related to gastrointestinal 
intolerability.
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Analysis
The incidence rate of the overall primary outcome and the specifi c types of 
outcomes were estimated by dividing the number of cases by the amount 
of accumulated exposure time. The duration of the diclofenac treatment 
was estimated from the prescription records as the legend duration (number 
of units prescribed divided by the number of units per day). Consecutive 
prescriptions were corrected for overlap. All analyses were conducted using 
SPSS version 11 (Chicago, IL).
Results
The source population of patients who were 18 years or older, actively 
registered at January 1st 2000 with at least 6 months of valid database history, 
comprised 163,767 subjects from 57 practices. In this source population, we 
identifi ed a total of 6191 patients diagnosed with osteoarthritis, 4974 patients 
(80.3%) with coded diagnosis of osteoarthritis and 1217 from validated free 
text hits.
Figure 1: Prevalence of osteoarthritis by age and gender at January 1st 2000 in the IPCI 
population.
Figure 1 shows the prevalence of osteoarthritis by age and gender. The 
prevalence increased with age and was higher among females. The overall 
consultation rate of the selected patients diagnosed with osteoarthritis was 
9.5 contacts per patient per year but varied largely by age (Figure 2). In total, 
5987 subjects had more than one year of follow-up. The median follow-up 
period was 1035 days (range: 275–1070 days). In 2000, 5691 (95%) out of 
48
Chapter 4
the 5987 subjects with at least one year of follow-up after January 1st, 2000 
contacted the GP at least once a year.
Figure 2: Contact rate of patients diagnosed with osteoarthritis by age.
Figure 3: Time to fi rst NSAID.
Figure 3 shows the time to receiving the fi rst NSAID prescription after the 
index date. After one year, about 40% of subjects had received at least one 
NSAID prescription. A total of 3663 patients (59.1%) received an NSAID 
during follow-up. The most frequently prescribed fi rst NSAID was diclofenac, 
followed by ibuprofen, naproxen and rofecoxib. In total, 1150 patients 
received a diclofenac prescription during the follow-up period.
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Figure 4 and Figure 5 show reasons for exclusion for the study population that 
received all kinds of NSAIDs prescriptions and only diclofenac prescriptions, 
respectively. About 30% of patients starting with an NSAID were excluded. 
For the patients starting with diclofenac, more than a third (35.7%) was 
excluded. The most frequent reasons for exclusion were recent use of NSAIDs 
and the use of gastro-protective agents.
 
Figure 4: Reasons for exclusion (according to the RDS protocol) among patients diagnosed 
with osteoarthritis and treated with a fi rst NSAID after January 1st 2000.
The majority of diclofenac users were female (71.7%) and about 20% of 
patients used diclofenac directly for osteoarthritis. In the 6 months prior to 
starting the diclofenac treatment, 3.6% of the patients used oral steroids 
and 4.9% used aspirin. During this period, the median duration of diclofenac 
use was 13 days while the risk of gastro-intestinal intolerability was 17.0% 
(95% CI 12.5–21.5). The incidence rate per 100 person-days exposure of the 
primary outcome was 0.25 (68 events in 26970 exposure days). In patients 
treated with diclofenac directly for osteoarthritis, the risk for gastrointestinal 
intolerability was 20.7% (95% CI 12.6–29.3) while the incidence rate was 0.27 
(22 events in 8278 exposure days). In the 12 months follow-up period the risk 
of gastrointestinal intolerability was 23.7% (95%CI: 17.3–30.0%).
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Figure 5: Reasons for exclusion (according to the study protocol) among patients diagnosed 
with osteoarthritis and treated with diclofenac after January 1st 2000.
Discussion
Our data have shown that the prevalence and the characteristics of patients 
diagnosed with osteoarthritis in the IPCI database are consistent with the 
literature.10,11 The risk of the primary outcome during use was about 20%, 
which is consistent with data from other studies.12,13 
We required that the minimal detectable rate ratio was 0.70. With an incidence 
rate of 0.25 cases per 100 person days of exposure, we would need 58,800 
exposure days to observe 147 events. We observed 26,970 days of diclofenac 
exposure in a period of 6 months follow-up. That means that for the RDS we 
would require about 2117 subjects ((58,800/26,970)*971) in each treatment 
arm.
In potential, there are enough patients diagnosed with osteoarthritis in the 
IPCI database to conduct the trial. However, there are some issues that need 
to be taken into consideration when deciding to conduct the trial in the IPCI 
database.
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About one third of eligible patients who start treatment with a diclofenac 
treatment are excluded mainly due to previous use of NSAIDs and gastro-
protective agents. We recommended not loosening the criteria, even though 
we may loose one third of potential patients. It would be diffi cult to determine 
if the outcome was due to the “old” or the “new” NSAID prescription in 
patients who recently switched from another NSAID the trial treatment the 
trial. Allowing patients who previously used an NSAID or a gastro-protective 
agent could also distort the results of the trial because, patients who use 
gastro-protective agents have a lower risk of the outcome.14,15 
Within one year of follow-up, 95% of selected patients see their GP at least 
once. The visit rate, nevertheless, was higher for elderly persons. To allow 
younger persons to be included as well, we recommended continuing the 
recruitment for at least one year.
The treatment duration with diclofenac was very low and the adherence 
was around 50%. Also, the number of days of follow-up that were covered 
with diclofenac was very low. We therefore recommended conducting rate 
analyses since this reduces underestimation of the relative risk (the majority 
of follow-up time is non-exposure time). 
The majority of patients (about 80%) diagnosed with osteoarthritis received 
diclofenac not directly for osteoarthritis. We initially proposed to allow other 
indications in the trial as well, but that would indicate that off-label use of 
NSAIDs (especially celecoxib) would be allowed in our randomised database 
study. Since celecoxib was only licensed for osteoarthritis and osteoarthritis 
related complaints, we had to limit the indication for NSAIDs use to these 
indications. We recommended allowing the inclusion of newly diagnosed 
(incident) patients with osteoarthritis to increase the chance of recruiting 
enough patients. 
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Abstract
The “randomised database study” strategy was fi rst proposed in 1997, with 
the aim to combine the generalisability of observational database studies 
based on electronic patient records and the validity of randomised clinical 
trials (RCTs). The key feature was to randomly assign treatments and to use 
routine care data, as available in the observational database for patient 
identifi cation and follow-up. To our knowledge, however, the idea of the 
randomised database study has not been implemented yet. 
The conduct of a randomised study in an observational database requires 
adjustments to the methods of medical information processing in the general 
practice. We developed a software system that facilitates the conduct of a 
randomised clinical trial with observational databases based on electronic 
patient records. It identifi es eligible subjects and presents them one by one 
to the physician once their electronic patient record is accessed. The general 
practitioner can start an interactive recruitment process and after completion, 
the computer randomises the patients. Follow-up is documented by normal 
routine care in the electronic patient record. 
Although the randomised database study has many methodological 
advantages, it has never been tested. Our software system is meant as a tool to 
implement and facilitate evaluation of the randomised database approach. 
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Introduction
The randomised controlled trial (RCT) is considered as the gold standard 
in clinical research. The main objective of a RCT is to evaluate whether 
an intervention is effi cacious.1 This evaluation is usually performed by 
randomisation, blinding, intensive patient monitoring, and strict management 
according to Good Clinical Practice (GCP) guidelines and protocols. Although 
these conditions facilitate the measurements of treatment effects, they limit 
generalisation of the results to other populations and settings.
Observational studies usually have a greater generalisability because they 
cover treatment patterns in normal care.2 Yet, the absence of randomisation 
in the treatment allocation often hampers sound comparison between 
treatments. Hence, observational studies are considered unsuitable for the 
evaluation of effectiveness of treatments.3,4 
General practitioners (GPs) are faced with the problem to apply evidence 
from studies that are conducted in strictly controlled settings to patients in 
normal care.5,6 Ideally, for them, evidence of treatment effectiveness should be 
obtained in routine care, in pragmatic randomised trials with patients normally 
seen by GPs.7 Although RCT in general practice may have better applicability 
to the primary care setting, there are many diffi culties in conducting them.8-10 
Frequently reported problems are lack of time, recruitment of investigators 
and patients, obtaining informed consent, randomisation, and data collection. 
However, most of the randomised studies in general practice use conventional 
methods for patient selection, recruitment, and data collection. 
A new approach that could facilitate RCTs in general practice is the randomised 
database study that was proposed by Sacristan and colleagues in 1997.11 This 
approach is based on the good experience with observational databases 
based on electronic patient records (EPRs) in the conduct of observational 
outcomes studies. An observational database is this context, contains data 
on regular patient care, which is collected for other purposes than research. 
Sarcristan argues that inclusion of a randomisation module in the EPR would 
allow assessment of drug effectiveness in a large population.12 The EPR would 
further function as a source for patient selection, and data collection during 
a naturalistic follow-up, like in observational studies. Although researchers 
recognized the advantages of the randomised database studies, to our 
knowledge it has not been implemented. 
The conduct of a randomised database study requires adjustments or additions 
to the regular medical information processing with the EPR system. The 
objective of this paper is to describe additions to the method of information 
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processing with an EPR system that facilitate the conduct of a randomised 
database study.
Method
The proposed adjustments in the data processing methods are meant to 
facilitate the conduct of a randomised study in the normal care process and 
are possible after installation of additional software in the EPR system. The 
RCT procedures and the proposed additions to the EPR system are described 
in Table 1. 
Table 1: Integration of the electronic patient record into randomized clinical trial 
procedures. 
Randomized trial procedure Integrated task of the electronic patient record
Patient selection The physician’s patient database is used to identify and fl ag 
all eligible subjects
Patient recruitment Additional software in the EPR may aid by reminding, and 
data preprocessing.
Informed consent Documentation of consent and reason for refusal of patients
Randomization Recruited patients are automatically randomized by a 
randomization module in the EPR
Data collection during follow-up Routine patient care data are used for outcome assessment
Setting
The setting of this study is an ongoing longitudinal general practice research 
database, the Integrated Primary Care Information database (IPCI). This 
database is described in more details elsewhere and has been used extensively 
for observational epidemiological and drug outcomes studies.13 In brief, 
the IPCI research database contains ELIAS EPRs of over 500.000 patients 
from 150 physicians throughout the Netherlands. The database comprises 
patient demographic information (date of birth, sex, anonymous patient 
identifi cation, insurance, date of registration and transferring out, date of 
death), medical notes, diagnoses both as codes and as free text, prescriptions, 
and indications for therapy, physical fi ndings, referrals, hospitalisations and 
laboratory values. The method we describe allows for a randomised study in 
the setting of the IPCI database.
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Patient selection
The fi rst procedure in the conduct of a RCT is the identifi cation and selection 
of potential patients (Table 1). The physicians or investigators usually do not 
systematically search for eligible patients and recruitment may be organized by 
asking consecutively presenting patients. Included patients are generally not 
compared with non-included eligible patients (since these are not identifi ed), 
therefore, little can be said about the generalisability of the data.14,15 
In our approach, the EPR database is used to select potential patients. With 
tailored software, the researchers may build queries to select eligible patients 
in the individual EPR systems. This method standardizes the selection procedure 
across research sites. An additional advantage is that all eligible subjects in 
the complete source population are identifi ed and marked. Availability of 
demographic and medical information on all eligible subjects in the database 
allows for detailed comparison of included and non-included patients and a 
better estimate of external validity. 
Patient recruitment
The second procedure in a randomised study is patient recruitment. GCP 
guidelines require a signed informed consent if a patient is randomised 
to treatment, even if these treatments are already licensed for marketing. 
Physicians often fail to recruit a suffi cient sample due to waning enthusiasm 
and the time needed to complete the recruitment procedure.16,17 Providing 
information and asking for participation is probably one of the major hurdles 
in recruitment, and little can be done to reduce the recruitment time. Due to 
lack of time and disruption of normal care, physicians perceive it as diffi cult 
to ask their patients to participate and to address all their questions during a 
normal consultation.18 
We developed an interactive software module with a reminder and data pre-
processing function to facilitate the recruitment process. As soon as the EPR 
of a selected patient is opened, the physician is informed about eligibility of 
the patient and is given the option to start the recruitment procedure. The 
software also enables researchers to monitor inclusion and the reasons for 
exclusion. 
Randomisation
In conventional multi-center clinical trials, randomisation usually occurs at 
one coordinating center. However, while centralized randomisation is often 
used, decentralized remote accesses, via web or telephone are increasingly 
employed. 
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With the EPR software, randomisation is conducted automatically in the EPR 
system after recruitment is fi nalized. The incorporated randomisation scheme 
should be unpredictable to avoid anticipation of treatment assignment by 
the GP, especially if the trial is not blinded. 
Data collection and patient assessment
Data collection in standard RCTs is often done by means of paper based case 
report forms and standardized questionnaires. Errors and incompleteness are 
monitored and corrected as far as possible by a clinical research organization. 
Even though this method ensures complete and accurate data, it is labor 
intensive. 
Since all the important clinical fi ndings and baseline characteristics are usually 
documented in the EPR, it can be used as the primary information source for 
baseline information and clinical outcome assessment.
 
Case study
We implemented a randomised database study to compare gastrointestinal 
tolerability of diclofenac and celecoxib in patients diagnosed with 
osteoarthritis. Project specifi c software has been built and implemented 
in the EPR systems of the participating GPs. The local EPR databases were 
used to select patients older than 18 years of age who were diagnosed with 
osteoarthritis. The patient selection was based on historical data in coded and 
free text format. Researchers reduce false positive hits by manually validating 
selections based on free text information. The software was installed in the 
EPR system of 42 GPs and it selected 7127 possible candidates. These patients 
were the source population from which the study population later emerged.
An electronic reminder was placed in the EPRs of selected patients to enable 
immediate recognition by the GP upon visits. If a patient diagnosed with 
osteoarthritis required a non-steroidal anti-infl ammatory drug treatment 
during that regular visit, the GP could start the interactive recruitment 
procedure that was facilitated by the software module. The GP could 
verify the inclusion criteria and exclusion criteria (i.e. contraindication) and 
the software documented the inclusion or reason for exclusion in the EPR 
system. As a result, we could quantify the number of patients who refused to 
participate, those excluded because of exclusion criteria and the number of 
patients ‘missed’ by the GPs. 
Immediately after written informed consent was obtained, the patient was 
allocated to diclofenac or to celecoxib by the randomisation software. The 
data that was recorded with the EPR during the naturalistic course of the 
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treatment was sent to the central observational database (IPCI). This database 
was used to assess outcomes as done in other observational studies. 
Discussion
In this paper, we proposed a method to include the electronic patient 
record in the conduct of a RCT and described the software for the practical 
implementation of a randomised database study. The major advantages of 
this method are fi rst the potential reduction of resources to conduct a study 
and secondly the availability of detailed information about the external 
validity since medical and demographic information of included and non-
included patients are available. 
Although the idea is attractive, the randomised database study is not without 
limitations or prerequisites. The successful implementation depends on 
the possibilities to interfere with the existing EPR system and the mode of 
information processing during normal practice. 
In order to minimize disruption of the normal consultation routines we 
inserted an electronic reminder system to alert the GPs about eligible patients, 
but subsequent steps had to be started by the GP. Although this leaves 
some freedom to the GP, it may also lead to non-inclusion and therefore 
selection bias. Because we had demographic and medical information on the 
entire source population it is always possible to estimate the magnitude of 
selection.
By national regulation, the GPs’ and at least the patients’ identity is confi dential 
in observational databases that are used for medical research.19 However, for 
the randomised database study named informed consent is required.20 The 
requirement to keep the level of privacy in line with national regulations 
increase the complexity of communication between the researchers, the 
research database organization, and the physicians. We used an extra 
identifi cation number on top of the anonymous IPCI number to avoid the 
possibility that the patient name was directly linked to the existing database 
number, which would lead to the possibility to have access to non-anonymized 
medical information in subsequent studies. 
The randomised database study approach is a clinical trial under the terms of 
the GCP guidelines. As a result, the principles of the GCP need to be followed 
which might reduce the possible resource savings. For example, if a patient is 
found to be eligible during a consultation extra time is necessary to explain 
the study and obtain informed consent. However the need for this extra time 
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cannot readily be anticipated and scheduled, which will create problems 
during busy consultations. 
With the randomised database study, it is diffi cult to adhere to the GCP 
requirements regarding documentation since the EPR, rather than a case 
report form is the primary data collection tool.20 GCP requires that source 
information cannot be altered. . An EPR can be changed retrospectively, which 
could go unnoticed if time stamping does not occur accurately. Therefore, the 
EPR may not be considered as a source document and a time-stamped printed 
version of the medical record in the database should be used instead.
Investigator recruitment is a major obstacle in the conduct of RCT in general 
practice. GPs recognize the need to improve evidence-based medicine in 
primary care, but their lack of participation in clinical trials is also evident.21-23 
GPs report the lack of support staff for research to be a major barrier to 
participate in RCTs. However, use of a clinical research nurse requires a change 
in the study strategy. It would not be cost-effi cient to recruit patients only 
when they present themselves at normal visits. Preferably, they should be 
called in actively. Although the proposed software may facilitate the conduct 
of a randomised study in general practice, it cannot remove all obstacles, and 
participation will always increase the workload. Suffi cient patient recruitment 
may therefore remain a problem even with the proposed methods. 
In summary, this paper describes our approach to actually implement 
the randomised database study. With adjustments and additions in the 
methods of information processing with the EPR the selection, recruitment, 
randomisation and data collection procedure of the RCT can be integrated in 
the normal care process. Our case study proved that it is possible. However, 
now that it is possible to facilitate the ‘randomised database study’ it should 
be evaluated on its validity and performance.
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Abstract
General practice research databases are increasingly used to study intended 
and unintended effects of treatments. However, confounding by indication 
remains a major problem. The randomized database study methodology 
has been proposed as a method to combine the strengths of observational 
database (generalisability) and the strength of the randomized clinical trial 
(RCT) design (randomization). 
We developed an infrastructure that enables the execution of randomized 
database studies with treatment randomization facilitated by a general 
practice research database. The requirements posed by the methodology of 
randomized database studies were facilitated by software components.
Our assessment showed that it is technically possible to conduct randomized 
trials in general practice according to the randomized database design. 
The infrastructure facilitated the conduct of randomized database studies 
in general practice but some practical diffi culties and methodological 
issues remain. The technical infrastructure seems to be both promising and 
potentially feasible to facilitate future randomized database studies, although 
the methodology needs to be evaluated in more detail.
65
A technical infrastructure to conduct randomised database studies
Background
An increasing number of general practitioners (GPs) replace traditional 
paper-based patient records with electronic patient records (EPRs). A typical 
EPR contains information about patient identifi cation, demographics, type 
of visits, prescriptions, diagnoses, reasons for visits, referrals, laboratory 
fi ndings and other notes. In the Netherlands, for example, more than 90% 
of the GPs have replaced their paper records with the EPRs.1 In automated 
general practices, the EPR facilitates many processes such as patient care, 
management, billing, planning of care processes, and education.2
Researchers have recognized the potential value of data collected with 
the EPR, and this realization has resulted in a number of so-called general 
practice research databases. These general practice research databases 
contain longitudinal data from the EPRs. In countries where the GP has a 
gatekeeper role in the healthcare system (e.g. the Netherlands, or United 
Kingdom), these databases contain almost complete medical data. Examples 
are the General Practice Research Database,3 Mediplus UK4 and Integrated 
Primary Care Information database.5
Pharmaco-epidemiology is an example of a research area that takes advantage 
of the availability of general practice research databases since the databases 
contain information on the population, drug use and mild and severe 
outcomes. However, a major issue in the conduct of observational studies, 
especially concerning intended drug effects, is confounding by indication*.6 
Such confounding occurs when the physicians’ selection of a treatment is 
related to the severity of the underlying disease or to the prognosis of the 
patient.7
In the randomized clinical trials (RCT) design, confounding is dealt with by 
random allocation of treatments.8 Even though the RCT design is considered 
the gold standard in asserting treatment effects, it has some limitations. RCTs 
are often conducted in controlled environments with selected and limited 
patient groups. One of the key challenges in the interpretation of RCT results, 
therefore, is to determine whether the study results also apply to other settings 
and populations. The term ‘generalisability’ is used to describe the degree to 
which the results can be generalized to other settings and populations.9 For 
example, a RCT conducted in a hospital environment controlled by a strict 
protocol with a specifi c patient population may not be generalisable to the 
general practice population. 
*Confounding by indication is a term used when a variable is a risk factor for a disease among non-exposed 
persons and is associated with exposure of interest in the population from which the cases derive, without 
being an intermediate step in the causal pathway between the exposure and the disease.
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Due to the lack of generalisability of RCTs to primary care settings, there 
has been a request for large simple trials or pragmatic trials that provide 
measures of treatment effectiveness (rather than effi cacy) in this setting.10 In 
pragmatic RCTs, the patient sample is more heterogeneous and the evaluation 
and follow-up criteria are similar to those used in clinical practice. Compared 
to conventional RCTs, pragmatic RCTs are conducted with fewer restrictions, 
and enable researchers to use study designs and data that are representative 
of the natural patient care setting.11 
A number of researchers have argued that combining the strengths of 
observational studies in databases (generalisability) and the strength of the 
pragmatic RCT design (randomization) will result in a new method of research: 
randomized database studies.13 A randomized database study is described 
as a study in which the EPR is used to select eligible study candidates, to 
randomize patients and to collect data on the course of the treatment.
Researchers use data collected during daily care to assess the outcome, as 
is done in pharmaco-epidemiological studies with general practice research 
databases. In a randomized database study, however, the randomization 
procedure needs to be incorporated in the daily care workfl ow, preferably 
when the treatment is prescribed.
Although the advantages of this approach have been recognized,13 no research 
has been conducted to further develop the randomized database study 
approach. In this paper, we describe our attempt to develop an infrastructure 
that enables the execution of randomized database studies with treatment 
randomization in the context of a general practice research database. 
We fi rst briefl y describe the changes that have to be made to the EPR in order 
to generate data for a general practice research database. We subsequently 
describe the additional system requirements posed by the randomized database 
study. Finally, we describe the different additional software components we 
built to enable the execution of randomized database studies.
Methods
From the EPR to a general practice research database 
Physicians in primary care mainly use the EPR to document patient treatment. 
Researchers using data from the EPR have concluded that data in the EPR are 
not always suitable for their needs,5 as the data requirements for research 
and clinical care are not always congruent. For example, researchers report 
that EPRs often contain in detail the actions performed by the physician, but 
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often not the underlying rationale;14,15 physicians often use the EPR to record 
“what was done” rather than “why it was done”. 
In the early 1990’s, we were involved in the development of a general 
practice research database based on EPRs used in general practice, the 
Integrated Primary Care Information (IPCI) database.5 When we developed 
the IPCI database, we analyzed the requirements of the researchers and built 
additional software to address the limitations of routinely recorded data 
when utilizing such data for research purposes. 
Requirement for observational research with the IPCI database
Researchers intended to use the IPCI database primarily for pharmaco-
epidemiological research; the database should be the data source to test 
hypotheses about both adverse and benefi cial effects of drugs. To enable 
investigators to conduct this type of research, we formulated the following 
requirements:
Researchers should have access to all medical data on the patients. Since 
GPs may record data in the EPR and on paper, we required that the GPs 
record all medical data in the electronic records. The general practices that 
supply data to the IPCI database should be paperless to ensure that all 
relevant events are recorded in the EPR.
Researchers should be able to follow treatments over time including 
changes in treatment. Therefore, GPs should record the indication for each 
prescription and switches to other treatments.
Researchers should not have to obtain informed consent from each 
individual patient for each study to avoid selective participation. The 
Dutch law stipulates that patient data can be used for research without 
the patient’s consent only if the data are anonymized.16 Therefore, we 
required the data in the IPCI database to be anonymous. This means that 
the identity of both the physicians and patients should be concealed to the 
researchers. 
Researchers anticipated that it would be impossible to predict all data 
requirements for future studies. For some studies, the data might be 
incomplete. We therefore required the ability to obtain additional data 
from the GP. 
 
Changes in the information processing with the EPR
In addition to the requirement that practices work paperless, three types 
of changes had to be made in the (information processing with the) EPR to 
enable the development of the IPCI database: changes in the data recorded 
1.
2.
3.
4.
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by the GP, changes in the communication with the EPR, and fi nally changes in 
the organization of the database.
Changes in the data recorded by the GP involved adding software to link 
prescriptions to indications. When the GP prescribes a treatment, the software 
asks the GP additional data about the indications and therapy changes. 
We added communication software that ensures the anonymity of the patient 
data and assigns a unique patient identifi cation number that would allow 
researchers to follow the patient over time. The GP is the only person who is 
able to translate that identifi cation number to the potential identity. After 
the patient has been anonymized, the communication software sends all data 
to the gatekeeper. The gatekeeper is a person responsible for the anonymity 
of the GPs. Finally, the data is stored in the central IPCI database. 
The organization of the IPCI database uses a board of supervisors, which has 
the responsibility to ensure the maintenance of the anonymity of patients 
and GPs. In addition, the board of supervisors has to approve each study 
proposal and researchers’ request to collect additional data. After the board 
of supervisors has approved a study, all individual GPs are informed about the 
study. The technical infrastructure of the IPCI project allows individual GPs to 
withdraw data on patients or specifi c data elements for studies.5 Patients are 
informed of the existence of the IPCI project by leafl ets and posters in the 
offi ce of the participating GPs. 
Currently, the IPCI database contains information from EPRs of about 150 
general practitioners (GPs) covering more than 500,000 patients and provides 
data for studies with various epidemiological study designs e.g. case-control 
design, cohort design, and cross sectional design.17-22 Conducting a study 
with the randomized database study method, however, was not possible in 
the IPCI database.
Towards randomized database studies with the IPCI database
To enable researchers to conduct randomized database studies, we fi rst 
analyzed the requirements posed by randomized database studies. Second, 
we built additional software to solve the shortcomings of the GP information 
system with respect to the conduct of randomized database studies. 
Requirements for a randomized database study
We analyzed the procedures in the conduct of RCTs in general in order 
to integrate them with the daily care process. Four essential steps were 
distinguished in the conduct of randomized trials that would apply to the 
randomized database study as well (Figure 1):
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Patient selection
Patient recruitment
Randomization of treatment
Follow-up of patients
Patient selection comprises the identifi cation of patients who are eligible for 
participation in a specifi c trial. Completeness of identifi cation of eligible patients 
is necessary to be able to assess whether the included group is representative 
for the total eligible population.23 There may be large differences between 
the included patients and the total eligible population, for example, if the 
included patients are healthier or if there is a large overrepresentation of one 
gender. In conventional randomized studies, the selection methods are often 
are not standardized and there is no information about the non-included 
persons, which severely limits the possibility to evaluate generalizibility.23
Patient recruitment in randomized trials involves the assessment of inclusion 
and exclusion criteria and obtaining informed consent from the patient. 
Researchers and recruiters are required to adhere to the Good Clinical Practice 
(GCP) guidelines.24 GCP is an international ethical and scientifi c standard for 
designing, conducting, performing, analyzing, and reporting clinical trials. 
One of the most important ethical principles of GCP is informed consent from 
participating patients: the recruiter should fully inform the patient about the 
study before the patient gives written consent to participate. In addition, the 
patients should have enough time to refl ect before consent is given. 
In randomized database studies, patients may be recruited during routine 
care visits.13 The constraints of the GP in recruiting patients during regular 
visits (i.e. time or disruption of the daily care process), however, needs to be 
addressed. The procedure itself should not be a disproportional disruption of 
the normal interaction between the GP and the patient.
Randomization in randomized database studies comprises the random 
allocation of treatment on a patient level. Randomization of treatments in a 
multi-center trial is often done centrally or by a local randomization procedure 
(i.e. envelopes, random number generator). To minimize disruption of the 
normal care process, the randomization procedure should preferentially be 
integrated in the workfl ow of the normal prescription routine. 
Patient follow-up in randomized trials are scheduled return visits to assess 
outcome parameters. Data are usually collected on case report forms. In the 
randomized database study, researchers use daily care data as recorded in 
the EPR to assess outcomes. This requirement poses two problems related 
to the GCP guidelines and the quality of the data. First, the GCP guidelines 
a.
b.
c.
d.
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require that the documentation of follow-up is accurate, complete, legible, 
and time-stamped and available for auditing. Second, study data derived 
from the source documents should be consistent with the source documents. 
If there are inconsistencies, the researchers should document and be able to 
explain them. There is a theoretical possibility that data in the EPR can be 
changed retrospectively, which could go unnoticed if time stamping does not 
occur accurately. An audit trail of the EPR, therefore, is an essential feature 
to comply with the GCP documentation guidelines.
Outcome assessment in the randomized database study approach will be done 
from the EPR data, but the quality and completeness of the data might not 
be optimal for all types of outcomes. For that reason, researchers required 
the possibility to collect data from the patient as well. At the same time, the 
researchers should maintain the level of confi dentiality required by use of the 
IPCI database.
Data on adverse drug reactions need to be collected according to regular 
spontaneous reporting schemes. Sudden unexpected serious adverse reactions 
and serious reactions have to be reported within 24 hours to the research 
center and the Netherlands Pharmaco-vigilance center in line with the newest 
European guidelines.25
Results
Changes in infrastructure to enable randomized database studies
We aimed to integrate the randomized database study with the daily care 
process in general practice by means of adding software to the general 
practice information system. The software consisted of different modules 
corresponding with the four essential steps in randomized studies: selection, 
recruitment, randomization, and follow-up of the patients.
Selection Module 
After installation of the software, the information system of the GP activated 
the selection module. The selection module contained the query that identifi es 
potential patients for a specifi c study based on data that was already available 
in the general practice information system (e.g. diagnosis, demographics, or 
laboratory fi ndings). The query may contain coded and free text searches 
but the latter required manual validation of the results to reduce the false 
positively selected patients prior to having them marked for recruitment. 
After the selection of potential patients, the selection module generated a 
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reminder with a special message in the EPR of the selected patients. Whenever 
the GP opened the patient’s EPR, the message reminded the GP that the 
patient had been selected as a potential subject for a study.
Figure 1: Steps in a randomised clinical trial and the software modules built to integrate the 
steps with the workfl ow of general practices working with an electronic patient record.
Recruitment Module
GPs were confronted with reminders in the EPRs of the selected patients 
whenever the patients´ EPR was opened. To minimize interference of the 
regular workfl ow, the GP had to start the recruitment module themselves 
whenever the patient was eligible for recruitment. 
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The recruitment module required completion of an automated questionnaire 
based on the inclusion and exclusion criteria that were formulated in the study 
protocol. Patients who fulfi lled the inclusion criteria, needed to give written 
informed consent before the GP could fi nalize the recruitment step. If the 
patient asked for time to refl ect, the recruitment module enabled the GP to 
postpone the decision to include the patient in the study and to continue later 
in time from that point on. The recruitment module also stored an electronic 
version of the patients’ informed consent for the research database. Once a 
patient was included or excluded, the software removed the reminder from 
the EPR. The user interface of the recruitment module was the same as the 
interface of the general practice information system.
Randomization Module
After fi nalization of the recruitment step, the randomization module 
allocated the patient to one of the treatment options. The software presented 
the results of the randomization procedure to the GP and verifi ed if the 
randomized treatment was actually prescribed. The recruitment module also 
assured equal allocation to the alternative treatments within a practice.26 
Follow-up Module 
We used the IPCI infrastructure to collect patient data but added a follow-up 
module that allowed researchers to collect data directly from the patients 
while maintaining the anonymity of the patients and the GPs. This was 
achieved by producing a new study number for each individual patient. This 
number differed from the patient number in the GP information system 
and the patient identifi cation number in the IPCI database. Researchers 
used this study number to collect data from patients by means of patient 
questionnaires, to communicate with the GP about the patient and to link the 
information with the IPCI database. To comply with the GCP documentation 
requirement, we retained a time-stamped printed version of the EPR and the 
patient questionnaires as source document.
Application
To test the feasibility and validity of a randomized database study, we compared 
the gastro-intestinal tolerability of celecoxib and diclofenac in patients 
diagnosed with osteoarthritis. Both celecoxib and diclofenac are non-steroidal 
anti-infl ammatory drugs (NSAIDs) licensed, marketed and reimbursed for the 
treatment of osteoarthritis. Due to preferential prescribing (i.e. channeling) 
of celecoxib to patients with gastro-intestinal and cardiovascular co-morbidity 
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in general practice,27 it was considered diffi cult to assess this study question in 
an observational study with a general practice research database. All patients 
diagnosed with osteoarthritis who needed an NSAID for osteoarthritis during 
routine GP visits, were eligible for entry in the study. During the recruitment, 
patients could be excluded if they were treated with an NSAID in the last 
three months or if they had any contraindication. After recruitment, patients 
were automatically randomized to diclofenac or celecoxib but the GP decided 
the dosage and treatment regimen. In the naturalistic follow-up, we focused 
on changes in NSAID treatment indicative of gastrointestinal intolerability 
(e.g., discontinuation of drug or adding gastro-protective agents). 
We recruited 42 GPs and implemented the software in their information 
system. We used the local EPR database in the general practice information 
system to select patients older than 18 years of age who were diagnosed 
with osteoarthritis. The selection module selected 7127 patients who met 
the selection criteria; for these patients, the selection module generated a 
reminder in the EPR. 
During a median patient-recruitment period of 188 days (range 26–261 
days), the GPs had contact with 4586 of the 7127 selected patients. When 
the GP accessed the EPR of these patients, the selection module displayed 
the message reminding the GP that these patients were selected for the 
randomized database study. The GPs prescribed NSAIDs to 1245 of the 4586 
patients. However, only 170 received the NSAID directly for osteoarthritis – 
these patients were potentially eligible patients for the study.
The objective of the recruitment module was to facilitate the recruitment 
procedure and it also documented the reasons for non-inclusion. Of the 170 
potentially eligible patients, 42 (24.7%) patients meet one of the exclusion 
criteria. Another 12 patients (7.1%) refused to participate. In 55 (32.4%) 
cases, the GP stated that he or she was not the principal healthcare provider 
treating the patient at the moment the patient was eligible for recruitment 
and therefore could not include the patient. In 30 cases (17.6%), the GP stated 
he or she was too busy to start the informed consent procedure. Finally, in 11 
cases (6.5%) the GP forgot to start the recruitment procedure. The remaining 
20 cases (11.8%) were included in the study and randomized to the treatment 
arms by the randomization module. By retrieving the EPRs of the included 
patients, we monitored the naturalistic course of their treatment. In addition, 
to study generalisability, the EPRs of the entire selected population were 
retrieved. 
Due to low number of eligible patients, the recruitment was less than our 
initial expectations and we planned to terminate the study. Events overtook us 
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when other researchers reported an increased risk for cardiovascular adverse 
events in patients treated with high dosage of celecoxib and we therefore 
terminated the study at that time.28
Discussion
In this paper, we describe our attempt to build an infrastructure to enable 
researchers to conduct a randomized database study in the IPCI general 
practice research database.
Our assessment shows that it is technically possible to conduct a randomized 
database study in a general practice research database and randomized clinical 
trials in the future. The shortcomings of the existing GP information systems 
that are the basis for the IPCI database, were solved by software modules that 
corresponded with the essential steps in the conduct of randomized database 
studies namely patient selection, recruitment, randomization, and follow-
up. Although the software facilitates the conduct of a randomized database 
study, some practical and methodological problems remain. 
Regarding practical issues, the number of eligible patients was less than 
expected. Patient recruitment depended on the visit-rate of the selected 
patients, and whether they required an NSAID treatment for osteoarthritis. 
In our study, we observed that more than a third of the selected patients did 
not visit the GP during the patient-recruitment period and almost half of 
the patients did not require an NSAID treatment. In addition, many patients 
received an NSAID treatment for other indications than osteoarthritis. 
The pressure on daily care in general practice is refl ected by the fact that the 
participating GPs were not always the principal healthcare providers treating 
the patient, or that they reported to be too busy, or they simply forgot to 
recruit the patient. These general practices related issues were the leading 
cause of non-inclusion (56.5%). Although we facilitated the recruitment 
procedure, it remains a disruption of the workfl ow of normal practice and it 
does require extra time, which may have limited the performance.29 
It is diffi cult to judge how the performance of the recruitment strategy in 
our randomized database study (11.8%) compares to other studies, due to 
the lack of data about their source populations. In one study comparing 
multiple patient recruitment approaches in a RCT conducted in primary 
care, the researchers reported that only 1.4% of all enrolled patients were 
recruited directly by the physicians.30 In this study direct physician recruitment 
was discontinued. Even though we cannot compare the percentages of this 
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study with our data directly, we conclude that our recruitment strategy was 
effective, but leaves room for improvement; alternative patient recruitment 
strategies should be considered in future studies. 
Several methodological issues remain regarding the implementation of the 
randomized database study design itself. The purpose of the whole endeavor 
was to circumvent confounding by indication while keeping the naturalistic 
follow-up procedure and outcome assessments. The gain obtained with 
removal of confounding may go at the expense of introducing a form of 
selection and information bias, which are absent in observational studies in 
the same research database. For example, due to time constraints, hesitance 
to recruit, or other issues, GPs may not recruit consecutive patients.31 As a 
result, only a selected population will enter the study, which may limit the 
generalisability of the results. 
Although we were able to verify patient-recruitment (information on 
eligible but non-included patients is available in the IPCI database and in 
the randomized database study software log), selective recruitment may 
limit both the sample size and the possibility to extrapolate the results to 
other populations.32 In addition, a naturalistic randomized database study is 
an open-labeled study (i.e. the GP and the patients are aware of the study 
question and the intervention). Due to this feature, information bias may 
occur if the follow-up and outcomes are recorded differently for the different 
study drugs.33
Conclusion 
In conclusion, we described an infrastructure that facilitates randomized 
database studies in the IPCI database. Technically, it is feasible to conduct 
studies in automated general practice according to the randomized database 
study design. The infrastructure built to conduct randomized database 
studies in general practice research databases, however, showed some 
practical diffi culties in the conduct of such a study and some issues that 
could jeopardize the validity of the methodology. Randomized database 
studies seem to be both promising and potentially feasible for future studies; 
the methodological issues, however, need to be evaluated in more detail.
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Abstract
Objective: To describe the implementation and practicalities of a randomised 
database study.
Method: An open label randomised database study was conducted in the 
Integrated Primary Care Information (IPCI) general practice research database. 
Software was inserted in the general practitioners information system to 
allow for automated patient identifi cation, recruitment, and randomisation. 
As an application, we compared gastrointestinal tolerability in persons who 
needed an NSAID for osteoarthritis and were randomised to either diclofenac 
or celecoxib. The exposures and outcomes were obtained from the electronic 
patient records in the IPCI database. To assess accuracy of exposure and 
outcome measures, we also collected information by self-administrated patient 
questionnaires. Reasons and characteristics of non-included eligible subjects 
were assessed to describe selection processes. Physicians were interviewed to 
evaluate the RDS and to identify the major obstacles.
Results: 42 GPs collaborated, and 7127 prevalent osteoarthritis patients were 
identifi ed. Among these subjects, 170 were eligible for recruitment (received 
an NSAID for osteoarthritis), 20 (11.8%) were randomized 54 (31.8%) were 
not recruited because of exclusion criteria 96 (56.5%) of the eligible patients 
were not recruited because the physician was too busy, or the patient was 
treated by another healthcare provider. Concordance between IPCI data and 
questionnaires for the outcome was good (Kappa 0.7; sd 0.14). Evaluation 
of the study with physicians showed that they appreciated the software but 
recruitment during routine visits was too time-consuming in particular since 
informed consent needed to be obtained.
Conclusion: Although a randomised database study is feasible from a 
technical and practical perspective, patient recruitment and time remain the 
major obstacles. This leads to selective inclusion, but the conduct of a RDS in 
a population-based database allows for quantifi cation of this bias.
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Background
Post-marketing observational studies are necessary to study safety and 
effectiveness of new drug treatments due to the limitations of randomised 
clinical trials (i.e. limited sample size (only frequent adverse effects are 
detected) and lack of generalisability due to: stringent in- and exclusion 
criteria and protocol-driven assessment).1 These observational studies are 
usually conducted with claims or medical record databases, since they refl ect 
real life practice, contain many patients and allow for fl exibility in study 
design.2 However, they suffer from potential confounding by indication 
due to the lack of randomisation and channelling of drugs to patients with 
prognostic differences.3
The randomised database study (RDS) was proposed as a solution to the 
poor generalisability of randomised clinical trials (RCTs) and the confounding 
problem in observational studies.4 In a RDS, the electronic patients records 
(EPRs) are used to identify possible candidates, to randomise treatments, and 
to collect data on the natural course of the treatment and outcomes. 
To our knowledge, the RDS design has only been described but has not 
been further developed and explored. Our question was whether the RDS 
would overcome the limitations of a standard RCT (effectiveness vs. effi cacy, 
better generalisability) and the standard observational study (confounding 
by indication). To test this we conducted a RDS with the aim to compare 
gastrointestinal tolerability of celecoxib and diclofenac in patients diagnosed 
with osteoarthritis who required a non-steroidal anti-infl ammatory drug 
(NSAID) for this condition. Due to premature termination of the study, we 
could not test whether celecoxib and diclofenac differed in gastrointestinal 
tolerability. The goal of this study is therefore to evaluate the implementation 
and conduct of a RDS with a special focus on patient recruitment, quality of 
outcome and exposure data, good clinical practice obligations and the GP’s 
opinion.
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Methods
Design 
A randomized database study was conducted among general practitioners 
who provide ongoing electronic patient record (EPR) data to the Integrated 
Primary Care Information (IPCI) database. The EPR data were used for exposure 
and outcome assessment, Identifi cation and randomization software was 
added to the GP’s information system to optimize time and recruitment.
Setting
The IPCI database has been described in detail elsewhere.5 In brief, IPCI is a 
general practice research database containing longitudinal data of more than 
500,000 patients registered with around 150 general practitioners (GPs). 
In the Dutch health care system, patients are registered with a GP who acts as a 
gatekeeper of medical care and information. The EPRs contain data on patient 
demographics, symptoms (using codes and free text), diagnoses (codes and 
free text), clinical fi ndings, referrals, laboratory fi ndings, prescriptions and 
hospitalisations. Summaries of the hospital discharge letters or information 
from specialists is entered in a free text format and hard copies can be 
provided upon request. Information on drug prescription comprises product 
name, quantity, strength, indication, prescribed daily dose, the Anatomical 
Therapeutic Chemical classifi cation (ATC) code, and the indication. To 
maximize completeness of the data, GPs who participate in the IPCI project 
are not allowed to use paper-based records. The IPCI project complies with 
European Union guidelines on the use of medical data for medical research 
and the database has been proven valid for pharmaco-epidemiological studies 
on drug safety, and effectiveness.5-8 
Application
We aimed to study the gastro-intestinal tolerability of celecoxib and 
diclofenac in patients diagnosed with osteoarthritis who required an NSAID 
for their osteoarthritis, with the RDS design. This application was chosen since 
a previous study had shown strong channelling of celecoxib to patients at 
higher risk of gastrointestinal and cardiovascular problems. An observational 
comparison would have suffered from strong confounding by indication.
The eligible study population comprised all patients 18 years and older, who 
were diagnosed with osteoarthritis and needed an NSAID for osteoarthritis. 
Patients were excluded if they had contraindications for the study drugs, 
were chronically using NSAIDs or used proton pump inhibitors or H2 receptor 
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antagonists. The study needed to include 4234 subjects (2117 in each arm) 
to show a reduction in the occurrence of gastrointestinal outcomes by 
celecoxib.
Patients were actively (with questionnaires) followed for a maximum of six 
months and passively (through the IPCI database) during and after 6 months. 
Patients were randomised to either celecoxib or diclofenac. The dose and 
duration of treatment was left to the decision of the GP, to refl ect real life 
practice. The primary outcome was defi ned as gastrointestinal intolerability 
leading to randomised treatment discontinuation; the addition of a proton 
pump inhibitor or H2 receptor antagonist; referral for endoscopy or referral for 
Helicobacter Pylori assessment. The outcomes were obtained from diagnosis, 
referral and prescription records in the IPCI database. To assess the accuracy 
of the exposure and outcome data, a self-administered questionnaire was 
supposed to complete 4 times (baseline and each week during the fi rst month). 
In addition, the occurrence of adverse effects were solicited by asking the 
patients whether they experienced nausea, diarrhoea, fl atulence, stomach 
pain/heartburn, headache, sleepiness, or skin rash. 
Data on adverse drug reactions and sudden unexpected serious adverse 
reactions needed to be reported by the GP to the Dutch Pharmaco-vigilance 
Center on separate forms consistent with the Good Clinical Practice 
guidelines.12
The Medical Ethics Committee of the Erasmus University Medical Center and 
the Scientifi c and Ethical Advisory Group of the IPCI project approved the 
study.
Randomized database study infrastructure and software architecture
The IPCI infrastructure was expanded to allow the conduct of a RDS, while 
taking into account Good Clinical Practice (GCP) guideline requirements.12 
Additional software incorporated in the general practice information systems 
to identify eligible candidates, to facilitate patient recruitment and to 
automatically randomise recruited patients. 
Upon installation of the software in the general practice information 
systems of the participating GPs, patients diagnosed with osteoarthritis were 
automatically selected as possible candidates. An electronic reminder was 
added to the EPRs of the possible candidates. Each time the EPR of a possible 
candidate was opened the message was displayed and if the patient required 
an NSAID treatment for osteoarthritis at that time the GP could initiate the 
recruitment procedure. Newly diagnosed patients with osteoarthritis (incident 
cases), could not be pre-selected by the software and for these patients, the 
GP had to remember study eligibility for these patients. 
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During the recruitment phase, the software guided GPs through the exclusion 
criteria. Finally, the patients had to provide written informed consent before 
they could be randomised. The additional study specifi c software documented 
the recruitment process for each possible candidate and stored the reasons for 
non-inclusion. Each time the GP did not start the recruitment procedure for a 
possible candidate, the software asked the GP to motivate the reason for non-
inclusion after closing the visit. The GP could choose between pre-specifi ed 
answers such as ‘the patient had no indication for an NSAID treatment’, ‘I was 
too busy’, ‘forgot to start the recruitment procedure’, or the GP could specify 
the reason in free text.
Recruited patients who consented to participate were randomised immediately 
in the GP’s offi ce by the software to either celecoxib or diclofenac (dose and 
duration was not fi xed). Since both drugs are licensed for osteoarthritis and 
reimbursed a regular prescription was printed that had to be fi lled in the 
pharmacy. 
Evaluation of the randomised database study
To evaluate the implementation of the RDS itself we 
described patient recruitment and selection processes in recruitment; 
compared information on exposure to celecoxib, diclofenac between the 
electronic patient record and the questionnaire; 
compared information on gastrointestinal outcomes between the electronic 
patient record and the questionnaire; 
assessed GP’s opinion about the RDS. Since the study was stopped prema-
turely we could not answer the study question whether celecoxib and 
diclofenac differed in gastrointestinal tolerability. 
To evaluate recruitment and selective in- exclusion, patients were considered 
eligible to be included when they received an NSAID treatment for 
osteoarthritis during a visit at the GP offi ce. Patients were not considered 
to be eligible for inclusion if they received a prescription after a telephone 
contact or at a home visit. Reasons for non-inclusion were categorized as 
follows:
Practice-related issues; GP listed the reason for non-inclusion as “ I was too 
busy” or, “ I forgot to recruit the patient”, or the GP who was treating the 
patient did not collaborate with the study. 
Patient-related issues; patient met exclusion criteria or refused to 
participate. 
1.
2.
3.
4.
a.
b.
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Selection (bias) in the inclusion procedure was assessed by comparing baseline 
characteristics between patients who were included and patients who were 
not included because of physician related issues.
Agreement between the EPR and the patient questionnaires was assessed by 
means of Kappa statistics for exposure to study drugs and outcomes.14
To evaluate GP’s experience with the RDS, GPs underwent a semi-structured 
interview at the closing-visit of the study. We asked the GPs to refl ect on 
their general thought of the RDS methodology, the issues encountered 
during the study and suggestions to improve the method. The interview 
focused mainly on feasibility, methodology and topic of the study. 
Table 1: The total number of participating general practitioners, the number of pre-
selected osteoarthritis patients per practice, the duration of participation in the study per 
GP and the included patients.
General 
practice 
number
Number of 
participating GPs 
within a practice*
Identifi ed 
possible 
candidates
Duration of 
participation 
of the GP **
(in days)
Possible 
candidates 
included
Incident 
cases***
1 4 370 152 1 1
2 1 177 183 1 2
3**** 2 1423 261 0 0
4 1 156 259 0 0
5 2 368 237 1 3
6 3 376 224 1 0
7 1 193 223 2 0
8 1 132 222 0 0
9 2 216 36 0 0
10 1 147 203 1 1
11 1 172 202 0 1
12 2 212 198 3 5
13 3 289 196 0 0
14 1 302 188 1 0
15 1 192 183 0 0
16 1 200 138 0 0
17 2 150 132 0 0
18 1 53 132 0 0
19 3 336 131 0 0
20 1 294 127 0 0
21 1 230 32 0 0
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General 
practice 
number
Number of 
participating GPs 
within a practice*
Identifi ed 
possible 
candidates
Duration of 
participation 
of the GP **
(in days)
Possible 
candidates 
included
Incident 
cases***
22 1 144 126 1 0
23 1 182 119 0 0
24 1 295 113 0 1
25 1 180 112 0 1
26 3 338 112 0 0
Total 42 7127 Median=188 20 15
* In group practices, different GPs may start on different points in time.
** In case of group practices, we reported the longest duration.
*** The General practitioners could also included newly diagnosed patients that were not selected by the 
software during installation of the RDS software.
**** Group practices where not all the GPs participated while the total number of possible candidates were 
selected.
Results 
Patient inclusion started on January 1, 2004 and was prematurely ended 
on December 17, 2004. Patient recruitment was slow and was not expected 
to improve. Recruitment of general practitioners was therefore stopped in 
September 2004 and patient recruitment was planned to stop on December 
31, 2004. The study was however, terminated on December 17, 2004 when 
Pfi zer announced an increased cardiovascular risk during use of celecoxib in 
the APC trial.13
Forty-two GPs (belonging to 26 practices) participated (Table 1). Together 
they covered a population of 141,395 patients. The median duration of 
participation per GP was 188 days (range 32–261 days). A total of 7127 
patients were identifi ed and fl agged as possible candidates for recruitment 
(on average 170 per GP). 
 More than a third of the pre-identifi ed candidates (n=2541, 35.7%), did 
not have any contact with the GP during the study period, 46.9% (n=3345) 
contacted the GP but did not receive an NSAID (Figure 1). A total of 1241 
(17.4%) subjects received an NSAID prescription, 517 of them were not eligible 
for recruitment with the RDS software because they received an NSAID 
during a telephone (with assistant) or home visit. Of the 724 patients who 
received the NSAID during an offi ce visit, 554 received the NSAID for another 
indication than osteoarthritis (Figure 1). Hence, during the follow-up period, 
170 (2.4%) of the 7127 possible candidates were eligible for recruitment. 
Twenty of the eligible candidates (11.8%) were randomised, 96 (56.6%) could 
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not be recruited because of practice-related issues. In 55 of these 96 cases, the 
patient received the NSAID from a healthcare provider in the general practice 
who was not participating in the study. In 30 cases (17.6%), the GP reported 
to be too busy to start the recruitment procedure, and in 11 cases (6.5%), the 
GP reported to have forgotten to recruit the patient.
n=170  
Figures 1: Flow diagram of possible study candidates in the randomized database study. 
Possible candidates were osteoarthritis patients that were automatically pre-selected by 
the specifi c study software.
Fifty-four out of the 170 eligible patients (31.8%) were not recruited because 
of patient-related issues. 25 of these 54 patients were excluded because they 
were either current or chronic NSAID users, 13 patients had a contraindication, 
12 patients refused to participate, and 4 patients (2.3%) were excluded 
because they were not eligible according to the GP. 
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During the follow-up period, 94 patients were newly diagnosed with 
osteoarthritis in the practices that participated in the study. Of these patients, 
26 (27.7%) received an NSAID prescription during a GP-visit and therefore were 
eligible for recruitment; fi fteen (57.7%) of these patients were recruited.
Of the thirty fi ve patients 20 received celecoxib and 15 diclofenac. Baseline 
characteristics were comparable between the two study arms. Comparisons 
of included prevalent OA patients with OA patients who were not included 
because of practice issues showed that the included patients were younger 
(mean age 60.2, sd 13.3 vs. 66.7, sd 11.1, p= 0.04) and had more contacts with 
their GPs (mean 30.9, sd 3.8 vs 14.8, sd 2.9, p= 0.01).
Data quality
The 35 included and randomised patients returned 83% of the questionnaires to 
the study center. Agreement between the EPR and the patients’ questionnaires 
regarding baseline exposure (drug name, dosage, and treatment regimen) was 
complete (Kappa 1.0). Data on outcomes, however, showed some differences 
between the EPR and the questionnaires but the agreement was good16 
(Kappa 0.7; SD 0.14) (Table 2). Ten patients reported to have stopped or 
changed the treatment before the prescription ended. The same information 
was reported in seven of the corresponding EPRs. The three cases in which 
there was no agreement between the EPR and the questionnaire regarded 
patients who stopped the treatment without consulting the GP. None of these 
patients stopped treatment because of gastrointestinal intolerability.
Table 2: Changes in baseline exposure indicative of study outcome (treatment change 
during the follow up period) from the electronic patient records and the patients’ 
questionnaires.
Patients’ questionnaires 
Exposure status during follow-up Total
No changes Changes/Stop 
Electronic Patient
Record*
No changes 24  3 27
Changes/Stop  1  7  8
Total 25 10 35
*Kappa statistic: 0.7 (SD 0.14).
 
GP perception
The majority of the participating GPs appreciated the developed RDS 
methodology. The automated selection, recruitment and randomisation 
procedures were the most appealing aspect of the methodology. 
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The main general criticism on the study was the lack of suitable patients. 
More specifi c problems were the high number of false positive reminders 
and diffi culty to recruit patients during routine visits. On average two 
messages per day were seen but the patients often came for other reasons 
than osteoarthritis. The necessity to inform the patient and ask for consent 
disrupted the normal workfl ow, especially since this had not been planned in 
the day schedule. 
Suggestions to improve the RDS methodology comprised use of the GPs’ 
assistant in the recruitment process, to recruit patients outside offi ce hours, 
and help of a research assistant.
Discussion
This RDS was not able to answer the study question whether celecoxib or 
diclofenac differed in gastrointestinal tolerability. Despite the premature 
ending of the study it has shown that a RDS is feasible and it has provided 
insight in the actual conduct, obstacles and possibilities of the design. 
Despite the recognized ease of participation and automated identifi cation, 
recruitment and randomization procedures, practice organization and 
time constraints remained the bottleneck in this study. We chose for the 
consultation as place of recruitment because it was considered the most 
naturalistic approach to enroll patients who acutely require an NSAID for 
osteoarthritis. The main problem was the time required to obtain informed 
consent, which is mandatory according to GCP even if both treatments are 
licensed and marketed for the indication.12 A second problem was topic 
related; most patients were not eligible for recruitment since they received an 
NSAID for another primary indication. Since our study was not a registration 
trial we did not allow off-label use. Another study specifi c problem was the 
fact that most patients obtained their NSAID through request of a repeat 
prescription during telephone or home consultation. Our software was not 
built to include patients outside of the offi ce and written consent could not 
be obtained during a telephone visit. 
By using the RDS methodology in an existing population-based general 
practice research database, it was possible to track and quantify recruitment. 
This allows for inspection of selective patient participation and recruitment 
which is an important limitation of regular trials.17,18 
We did not require completion of case report forms because this is known 
to be time consuming and the source documentation was assumed to be 
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available in the EPRs. We assessed whether the quality of data in the EPR was 
good but we also acknowledge that this depends on the type of outcome. 
Quality of data in the EPR is likely to be better when the outcome is more 
severe. In our small study concordance was good between EPR data and the 
patient questionnaire on the outcomes. 
After evaluation of the trial and interviews with the GPs, we concluded that 
it is technically feasible to conduct a randomized database study. There is a 
potential to benefi t from the strength of the RCT design (randomization) and 
the observational study (generalisability). A major hurdle in our randomized 
database study was patient recruitment (during routine consultations). 
Alternative patient recruitment approaches need to be investigated to 
improve the feasibility of randomized database studies. The potential of 
the randomized database study, however, is clear and there should be more 
research to increase the performance.
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Summary
In 1997 Sacristan and colleagues posed the idea of randomised database 
studies as a possible solution for the weaknesses of observational studies 
(confounding) and randomised clinical trials (generalisability) in the evaluation 
of drug effects. 
The randomised database study (RDS) was proposed as a study with the 
following characteristics: computerized selection of potentially eligible 
candidates, randomization of patients to one of the treatment arms, and 
naturalistic follow-up of patients with routine care data in general practice 
databases (as in observational studies). Because of the naturalistic follow-up, 
results from a RDS would be better generalisable to the general population 
and would not suffer from confounding because of the random treatment 
assignment. The potential benefi ts of the RDS can be easily recognized, 
however to our knowledge this research methodology has only been described 
and has not been tested. We further developed the RDS methodology and 
tested its feasibility in the Integrated Primary Care Information (IPCI) general 
practice research database. 
Application of a randomised database study in the IPCI database
To test the feasibility of the randomised database study we aimed to compare 
the gastrointestinal tolerability of celecoxib and diclofenac in patients 
diagnosed with osteoarthritis. Celecoxib and diclofenac are non-steroidal 
anti-infl ammatory drugs (NSAIDs) licensed, marketed and reimbursed for 
the treatment of osteoarthritis. Diclofenac is a non-selective NSAID that is 
commonly used for the treatment of arthritis, pain and stiffness. Due to 
the inhibition of cyclo-oxygenase-1 (COX)-1, use of diclofenac is associated 
with a 2- to 3-fold increased risk of upper gastrointestinal complications 
such as bleeding, ulcers and perforation. Celecoxib is a COX-2 selective 
inhibitor (coxib) with effi cacy comparable to non-selective NSAIDs but with a 
signifi cantly lower risk of endoscopically confi rmed gastro-intestinal lesions 
and a tendency to less serious upper gastrointestinal events. The comparison 
of gastrointestinal tolerability of these drugs was chosen as test case since we 
hypothesized that an observational comparison would not be feasible due 
to channelling of coxibs to patients at higher risk of upper gastrointestinal 
complaints and therefore confounding by indication. The existence of 
channelling, confounding by indication was fi rst evaluated in observational 
studies and subsequently the RDS was designed, developed and tested.
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Proof of concept studies 
In Chapter 2 we conducted a retrospective cohort study in the IPCI general 
practice research database. It was demonstrated that coxibs with comparison 
to non-selective NSAIDs are preferentially prescribed to patients with more 
risk factors for NSAID-related gastrointestinal disorders. That phenomenon is 
known as channelling (bias). We observed that coxib users more frequently 
had one or more risk factors for NSAID-related gastro-intestinal disorders (OR 
1.18, 95% CI 1.10–1.26). In addition coxib users more often had cardiovascular 
disease (independent of gastrointestinal risk) (OR 1.35 95% CI 1.28–1.43). This 
channelling phenomenon was present from the moment of launch until the 
moment of data drawdown (end of 2004). Due to the channelling of coxibs, 
it was considered diffi cult to compare the gastrointestinal tolerability of 
celecoxib and diclofenac without randomised assignment of treatment. 
To illustrate the weakness of observational studies on (benefi cial) treatment 
effects, we studied whether coxibs lowered the risk of upper gastrointestinal 
bleedings or ulcers compared to the one pill combination of diclofenac 
and misoprostol. The one pill combination of diclofenac and misoprostol is 
an alternative NSAID regimen, which is also indicated in patients with an 
increased risk of NSAID-related gastrointestinal disorders due to the gastro-
protective effects of misoprostol. Chapter 3 shows that use of coxibs increases 
the risk of gastrointestinal bleeding or ulcers as compared to the one pill 
combination of diclofenac and misoprostol. Despite the fact that both coxibs 
and the one pill combination of diclofenac and misoprostol are indicated 
for the high GI-risk population, we could not exclude that our fi ndings were 
due to residual confounding by indication. We adjusted for all measurable 
risk factors that affected the point estimate, but only random treatment 
assignment may deal with measurable and immeasurable differences in risk 
factor patterns. We therefore proposed to conduct a randomised database 
study in the IPCI database. 
We conducted a pilot study (Chapter 4) to assess the sample size required for 
the randomised database study. The minimal detectable rate ratio was set at 
0.70, α at 0.05 and the power at 80%. Given the event rate, required events 
and the mean treatment duration it was estimated that about 2117 subjects 
in each treatment arm would generate the required persontime and events.
Randomised database study
Chapter 5 and 6 describe the development, concept and implementation of the 
randomised database studies in the IPCI general practice research database. 
We used the general practitioners’ information system with electronic patient 
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records as a tool to identify possible candidates (pre-selection), to facilitate 
the recruitment process and to randomise treatments. The IPCI database with 
the electronic medical records of the same patients was used to collect data 
on patient follow-up. Since we anticipated that the outcome data in the 
electronic medical records could be incomplete, patient questionnaires were 
administered as concomitant data collection method to assess the quality of 
data in the electronic medical record. 
In Chapter 6, we further describe the changes to the IPCI infrastructure 
that were required for the conduct of the RDS. All pre-selected patients 
automatically received a study number, which could be linked to the IPCI 
identifi er. This study number enabled us to follow the patients from the day 
of selection until the end of the study. As a result we could track whether pre-
selected patients visited the GP, reasons for non-inclusion, the outcome of the 
randomisation procedure and eventually study outcomes. We concluded that 
it was technically feasible to conduct a randomised database study in the IPCI 
general practice research database. 
We conducted an evaluation study to describe the issues we encountered 
and interviewed GPs to obtain their perception of the randomised database 
study methodology (Chapter 7). In the study period between January and 
September 2004, we recruited 42 general practitioners, in these practices 
7127 patients were considered eligible for inclusion. During the follow-up 
period (terminated early in December 2004 because of slow recruitment 
and uncertainty about cardiovascular safety of celecoxib), more than a third 
(35.7%) of the possible candidates did not have any contact with the GPs and 
almost half (46.7%) of the patients who contacted the GP did not require 
NSAID treatment. This was important because we only considered patients 
to be eligible if they received an NSAID treatment for osteoarthritis during 
a regular visit with their GP. Patients who were treated with an NSAID often 
received it for another indication than osteoarthritis or they received the 
NSAID during a telephone contact or home visit. In total, 170 patients were 
eligible for recruitment of which twenty (n=20) were recruited. Most of the 
other eligible patients (88.3%) could not be recruited because of practice-
related issues (n=96.) (i.e. GP prescribing the NSAID was too busy, or GP was 
not the principle healthcare provider) and patient related issues (n=56) (i.e. 
exclusion criteria, refusal to participate and GPs exclusion based on their own 
opinion). 
From the interviews with the participating GPs we learned that almost all of 
them appreciated the methodology. The GPs reported that the automated 
procedures were the most appealing aspect of the study. The most important 
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weakness of the RDS was reported to be timing of recruitment which was 
during regular visits. The recruitment procedure disrupted the normal 
workfl ow. 
Our assessment of the quality of information showed that the EPR is an 
excellent tool to obtain information on prescriptions and outcomes that lead 
to a GP visit. The EPR was incomplete on reasons for stopping treatment. 
Discussion and Recommendations
The main objective of this thesis was to implement and test the randomised 
database study, which conceptually should bridge the gap between 
observational studies and randomized clinical trials.
Randomized trials
The randomised controlled trial (RCT) is considered as the gold standard 
in clinical research. The main objective of a RCT is to evaluate whether 
an intervention is effi cacious.1 This evaluation is usually performed 
by randomisation, blinding, intensive patient monitoring, and strict 
management according to Good Clinical Practice (GCP) guidelines and 
protocols. Although these conditions facilitate the measurement of 
treatment effects, they limit generalisation of the results to other populations 
and settings. Evidence in respiratory research has demonstrated that RCTs 
include <10% of the eligible population for treatment who present to 
physicians’ offi ces2 (Table 1). These data underline the importance of the 
selection problem. However in most clinical trials the selection process is 
unknown since the source population is usually not quantifi ed.
Table 1: Number of asthma patients remaining in clinical trials after stepwise introduction 
of selection criteria for an asthma RCT according to WHO criteria2.
Number Percentage
Clinical asthma (seeking primary medical care) 334 100.0
FEV1 50–85% of predicted 124 37.1
Reversibility 12% with ß-agonist use 50 15.0
No co-morbidity 32 9.6
Pack-years smoked <10 18 5.4
Regular use of ICS 15 4.5
Symptomatic asthma (eligible for asthma RCT) 11 3.3
General practitioners (GPs) are faced with the problem of applying evidence 
on drug effi cacy from studies that are conducted in strictly controlled 
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settings with a very homogeneous patient group to the heterogeneous and 
uncontrolled situation of their normal care.3,4 Ideally, for them, evidence of 
treatment effectiveness should be obtained in routine care, in pragmatic or 
naturalistic randomised trials with patients normally seen by GPs.5 
Although trials in general practice may have better applicability to the primary 
care setting, there are many diffi culties in conducting them.6-8 Frequently 
reported problems are lack of time, recruitment of investigators and patients, 
obtaining informed consent, randomisation, and data collection. Most of 
the randomised studies in general practice still use conventional methods 
for patient selection, recruitment, and data collection. Our belief was that 
making use of the automated patient record potentially could facilitate the 
process of patient selection and data collection. 
Observational studies
Postmarketing observational studies are necessary to study safety and 
effectiveness of new drug treatments due to the limitations of randomised 
clinical trials (i.e. limited sample size – only frequent adverse effects are 
detected) and lack of generalisability due to stringent in- and exclusion 
criteria and protocol-driven assessment.9,10 These observational studies are 
usually conducted with claims or medical record databases; they refl ect real 
life practice, contain many patients, and allow for fl exibility in study design. 
Observational studies on drug effects usually have a greater generalisability 
because they cover treatment patterns in normal care.9 Yet, the absence of 
randomisation in the treatment allocation often troubles sound comparison 
of effects between treatments. Although observational studies have been 
pivotal in the assessment of adverse drug reactions, they are considered as 
less suitable for the evaluation of effectiveness of treatments.11,12 In most 
instances the occurrence of an adverse drug reactions is not related to the 
severity or indication of the drug, whereas the intended benefi t of the drug 
is highly associated with the indication or severity.13
Randomised database study
A new approach that could facilitate trials in general practice is the randomised 
database study that was proposed by Sacristan and colleagues in 1997.14,15 
This approach is based on experience with observational databases based on 
electronic patient records (EPRs) in the conduct of observational outcomes 
studies. Sacristan argues that inclusion of a randomisation module in the 
EPR would allow assessment of drug effectiveness in a large population.14,15 
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The EPR would further function as a source for patient selection, and data 
collection during a naturalistic follow-up, like in observational studies. The 
conduct of a randomised database study requires adjustments or additions 
to the regular medical information processing with the EPR system and the 
purpose of this thesis was to describe these and test the RDS design. 
Main fi ndings
In the initial part of this thesis, proof of concept was given by demonstrating 
that channelling occurs with the prescription of selective COX-II inhibitors 
(coxibs) in comparison to non-selective NSAIDs. Patients who received 
coxibs had a signifi cantly higher prevalence of risk factors for NSAID-related 
gastrointestinal disorders and a higher prevalence of cardiovascular diseases/
conditions; this was independent of the practice the patient belonged to. 
Although the extent of channelling changed slightly during the study period, 
channelling remained signifi cant. 
As a second proof of concept study to underline the need for a RDS, a case 
control study was conducted in a cohort of NSAID or coxib users to assess 
whether use of coxibs was associated with a lower or comparable risk of upper 
gastrointestinal ulcers and bleedings in comparison to the one pill combination 
of diclofenac and misoprostol (Arthrotec®). This drug is an alternative NSAID 
regimen, which is indicated in patients with an increased risk of NSAID-related 
gastrointestinal disorders due to the gastroprotective effects of misoprostol. 
This comparator was chosen to reduce the risk of confounding by indication. 
Coxibs increased the risk of gastrointestinal bleeding and ulcers as compared 
to the one pill combination of diclofenac and misoprostol. Despite the fact 
that both coxibs and the one pill combination of diclofenac and misoprostol 
are indicated for the high GI-risk population, we could not exclude that our 
fi ndings were due to residual confounding by indication. 
The remaining of the thesis is dedicated to the exploration, implementation 
and evaluation of the RDS method. The main fi nding is that the RDS method 
is technically feasible; we could implement a randomized database study in an 
existing general practice research database. The recruitment process, however, 
needs to be changed. The methodology is appealing to both the general 
practitioners and researchers. The following advantages were observed:
Easy access to a large heterogeneous population refl ecting the general 
population;
Automated patient selection, randomisation and data collection with the 
EPR, which reduced time investment and loss to follow-up;
1.
2.
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Elimination of confounding by randomly assigning treatments;
The ability to study the source population from which the study population 
emerges and to quantify selective recruitment and participation.
Access to the source population from which the study population emerges gives 
the unique opportunity to study issues that could affect the generalisability 
of the study results.15 For example, we could exactly track reasons for non-
inclusion, we could study whether the participating population differed in 
characteristics from the non-participating population, and we could evaluate 
whether outcome occurrence was different in the included and non-included 
population. The fact that the complete medical records are collected for all 
patient in the practice – included in the trial or not – enables such a detailed 
analysis. In addition we could study whether participation in the study 
changed the behaviour of the GPs (Hawthorne effect).5 
Despite the recognized advantages, conducting the RDS revealed unforeseen 
problems; these problems will be described below. 
A RDS is considered to be an interventional study since treatment assignment 
is randomised. Therefore, researchers should follow the principles of the 
Good Clinical Practice (GCP). Adherence to these guidelines proved to be a 
signifi cant hurdle that required time and effort on the part of the GP. For 
example, GPs have to obtain written informed consent from every individual 
patient. Although in absolute terms GP workload was reduced in comparison 
to a conventional trial it became clear that a naturalistic trial always remains 
time consuming. Moreover, the naturalistic trial does disrupt the normal fl ow 
of the practice. In the RDS described in this thesis, we only recruited patients 
during regular visits – randomization had to be done at the time a patient 
required new NSAID treatment. Most of the problems we encountered 
were related to the fact that the moment of inclusion was at the time GP 
decided to prescribe a NSAID. At that point in time, typically at the end of the 
consultation, randomization should occur and patients had to be recruited. 
The recruitment process itself was time consuming and could not be planned 
in advance – the burden of the recruitment process was the factor limiting 
inclusion. One of the most important lessons learnt was that, in a future RDS, 
recruitment should be organized differently. Options suggested by the GPs 
included to specifi cally invite potentially eligible patients outside of routine 
consultation hours, or to block a double consultation for potentially eligible 
patients. 
3.
4.
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Blinding is a feature that is not a part of the current RDS methodology. The 
open study character may result in bias if outcomes are recorded differently 
per treatment arm. Our data showed that GPs had the tendency to record 
more data on patients treated with celecoxib compared to patients treated 
with diclofenac. Therefore blinding assessment of the outcome should be 
considered in future RDS. 
We also have encountered unforeseen logistical issues that had a signifi cant 
impact on the study. In the RDS we conducted, patients could only be 
recruited during visits at the GP’s offi ce since they had to provide written 
consent. However a large percentage of the eligible patients received the 
NSAID prescription, which would allow them to be included in the study, 
during a telephone consultation. Especially for chronic diseases, telephone 
consultations are a frequent alternative to face-to-face encounters. Future 
studies with similar designs should therefore include recruitment options for 
patients who receive the inclusion qualifying medication through telephone 
consultations.
Most patients diagnosed with osteoarthritis, received NSAIDs for another 
indication than osteoarthritis. According to the Good Clinical Practice 
guidelines, these patients could not be included since off-label use (even if 
such off-label use is widely applied in clinical practice) cannot be promoted in 
a non-registration trial.19 
GCP requires that source information cannot be altered or otherwise that all 
changes in source documents are signed off. Data in the EPR system, which 
we considered to be the source documents, can be changed retrospectively 
and therefore the EPR itself can not be considered the source document in 
all instances. We used a time-stamped versions of the medical records in the 
database to comply with GCP guidelines. It should be discussed with competent 
regulatory bodies whether this solution will stand up in case of dispute.
In conclusion, the RDS design is an elegant alternative to the resource intensive 
randomised clinical trials conducted in general practice. The RDS methodology 
does combine the strengths of the RCT design and that of observational 
studies. On the other hand, it also combines the weaknesses of both the RCT 
design and observational studies. The adherence to the ethical requirements 
posed by the GCP guidelines, for example, may reduce the avowed benefi ts 
in terms of the resource savings. Physician and patient recruitment is an issue 
in the conduct of a RDS, as well as blinding and potential selection.
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Recommendations
We formulated a few recommendations to improve future randomized 
database studies. 
The research topic in a randomized database study should be of immediate 
interest for the GPs and refl ect a clinical important question with genuine 
equipoise about the differential benefi t of one or the other treatment.19 If 
some of the participating GPs have prior believes that one of the treatments 
is superior, it may result in lack of compliance or information bias in the 
data collection procedure. 
RDS protocols should be easy to follow and have a robust outcome. 
Soft outcomes might not lead to a GP encounter and therefore may go 
unnoticed. To avoid differential misclassifi cation in outcomes, researchers 
should consider collecting data also directly from patients.
To render a randomized database study feasible with large numbers 
patient, recruitment should be organized outside the regular visit. 
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Samenvatting
In 1997 lanceerden Sacristan en collegae het idee van gerandomiseerde 
database studies (RDS) voor onderzoek naar effecten van geneesmiddelen. 
Een RDS zou de oplossing zijn voor de confounding problematiek in 
observationale studies naar geneesmiddel effecten die vaak uit worden 
gevoerd in databases van geautomiseerde patienten dossiers en het gebrek 
aan generaliseerbaarheid van gerandomiseerde klinische trials.
Een RDS werd gepresenteerd als een studie met de volgende karakteristieken: 
automatische selectie en randomisatie van mogelijke participanten, en 
een naturalistische follow-up door middel van data die is verzameld in de 
elektronische medische dossiers (EMDs) van de participanten. De analyse van 
een dergelijke studie kan vervolgens worden uitgevoerd met gegevens die uit 
de database worden gehaald (zoals bijvoorbeeld IPCI). Omdat het hier om een 
naturalistische follow-up betreft, zullen de resultaten uit een RDS waarschijnlijk 
beter generaliseerbaar zijn en de randomisatie van behandelingen zou het 
confounding probleem oplossen. Ondanks de potentiële voordelen van de 
RDS zijn er geen publicaties bekend van studies die op deze manier zijn 
uitgevoerd. Wij hebben daarom de RDS methodologie verder ontwikkeld en 
de haalbaarheid getoetst in de IPCI onderzoeksdatabase.
RDS in de IPCI database
Om de haalbaarheid van de RDS methodologie te toetsen hebben we 
een sponsor gevonden die geinteresseerd was in de vergelijking van 
gastrointestinale verdraagzaamheid tussen celecoxib en diclofenac bij 
patiënten met artrose. Celecoxib en diclofenac zijn geregistreerde niet 
steroidale ontstekingsremmende geneesmiddelen (NSAIDs) die werken 
via remming van cyclo-oxygenase (COX) en zijn geïndiceerd voor onder 
andere de behandeling van artrose. Diclofenac behoort tot de groep COX 
niet selectieve NSAIDs en wordt behalve voor artrose ook voorgeschreven 
aan patiënten met pijn en stijfheid (in de gewrichten). Doordat diclofenac 
niet selectief is voor COX-2 maar ook COX-1 remt, verhoogt het de kans op 
gastrointestinale klachten zoals bloedingen, ulcers en perforaties. Celecoxib 
behoort tot de categorie NSAIDs die selectief COX-2 remmen (coxibs) en 
heeft een vergelijkbare effectiviteit als de niet selectieve NSAIDs, maar een 
lagere kans op endoscopische vastgestelde gastrointestinale klachten. De 
vergelijking van de gastrointestinale klachten van deze twee types NSAIDs 
werd in de RDS gekozen als test case. 
We hadden verwacht dat we deze vergelijking middels observationele 
studies niet goed zouden kunnen doen omdat COX-2 remmers selectief 
worden voorgeschreven en aangeraden aan patiënten met een hoger risico 
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op gastrointestinale klachten. Dit wordt ook wel “channelling” genoemd. 
Channeling is een belangrijke oorzaak van confounding. Om deze aanname te 
onderbouwen hebben we channelling van COX-2 remmers in kaart gebracht, 
een observationele vergelijking van geneesmiddel effecten gedaan middels 
een geneste case controle studie uitgevoerd. Uiteindelijk hebben we een RDS 
studie opgezet.
‘Bewijs van concept’ studies
Hoofdstuk 2 is een beschrijving van een cohort studie waarin coxib gebruikers 
worden vergeleken met niet-selectieve NSAIDs gebruikers. Deze studie laat 
zien dat coxibs selectief worden voorgeschreven aan patiënten die intrinsiek 
een hoger risico op gastrointestinale klachten hebben. De analyse laat ook 
zien dat coxib gebruikers meer cardiovasculaire co-morbiditeit hebben 
(onafhankelijk van de gastro-intestinale risico) (OR 1.35 95% BI 1.28−1.43). 
De channelling trad op vanaf het moment van marketing van coxibs en 
bleef aanwezig tot aan het moment van deze studie (eind 2004). Vanwege 
de channeling is het dus moeilijk om de gastrointestinale verdraagzaamheid 
van celecoxib te vergelijken met diclofenac zonder de participanten te 
randomiseren, hoewel statistisch geadjusteerd kan worden voor meetbare 
verschillen tussen patienten, kan confouding van niet meetbare factoren 
nooit uitgesloten worden. 
Om het probleem van observationele studies verder te illustreren, hebben 
we een studie uitgevoerd waarin werd gekeken of coxibs het risico op 
gastrointestinale bloedingen of ulcers verlaagt ten opzichte van de 
vaste combinatie van diclofenac en misoprostol. Deze combinatie is een 
alternatieve behandelstrategie voor patiënten met een verhoogd risico 
op NSAID gerelateerde gastrointestinale klachten. Hoofdstuk 3 laat zien 
dat het gebruik van coxibs geassocieerd was met een verhoogd risico op 
gastrointestinale bloedingen en ulcers in vergelijking tot de combinatie van 
diclofenac en misoprostol. Wij kunnen in deze studie echter niet uitsluiten dat 
de resultaten vertekend zijn door residuele confounding ondanks het feit dat 
beide behandelstrategieën voor patiënten met een verhoogde risico bedoeld 
is. Er is gecorrigeerd voor alle meetbare risicofactoren die de geschatte risico 
zou kunnen beïnvloeden, maar alleen randomisatie van de participanten 
garandeert vergelijkbare risicopatronen van deze twee populaties. We 
hebben daarom een RDS in de IPCI database voorgesteld.
Hoofdstuk 4 beschrijft een pilot studie die werd uitgevoerd het minimale 
aantal RDS participanten vast te stellen. De minimale detecteerbare ratio was 
gezet op 0.70, de α op 0.05 en de power op 80%. Gegeven de ratio van de 
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uitkomst, het aantal events en de gemiddelde behandelduur is er geschat dat 
er 2117 participanten per behandelarm nodig waren om de persoonstijd en 
events te genereren.
Gerandomiseerde database studie
In hoofdstuk 5 en 6 worden concepten en de implementatie van de RDS 
in de IPCI onderzoeksdatabase beschreven. We hebben de EMDs in de 
huisartsinformatiesystemen gebruikt om potentiële kandidaten te selecteren, 
om het rekruteringsproces te ondersteunen en om de participanten te 
randomiseren. De EMDs, die later in de IPCI database worden geïntegreerd, 
werden ook gebruikt om de gerekruteerde patiënten te volgen. Omdat we 
hadden geanticipeerd dat de EMDs niet altijd volledig zouden zijn, hebben 
we ook via de participanten door middel van vragenlijsten data verzameld. 
Met deze data konden we de kwaliteit van de data in de EMDs vaststellen. 
In hoofdstuk 6 worden de veranderingen beschreven die nodig waren om 
de IPCI infrastructuur geschikt te maken voor een RDS. Alle geselecteerde 
patiënten (potentiële kandidaten) kregen een studienummer, die werd 
gekoppeld met het IPCI- studienummer. Op deze manier waren wij in staat 
om de patiënten te volgen vanaf de dag van de selectie tot het einde van 
de studie. Deze koppeling maakte het ook mogelijk te verifi ëren wanneer 
de geselecteerde patiënten hun huisarts hebben bezocht, waarom ze niet 
in de studie zitten, de uitkomst van de randomisatie en de eventuele studie 
uitkomst. Deze infrastructuur liet zien dat het technisch mogelijk was om een 
RDS uit te voeren in de IPCI onderzoeksdatabase.
In de evaluatie studie (Hoofdstuk 7) beschrijven we de praktische issues en 
feedback van huisartsen over de RDS. In de studie periode tussen januari 
en september 2004 hebben we 42 huisartsen gerekruteerd met een totale 
populatie van 7127 potentiële artrose patiënten. Gedurende de follow-up 
hadden meer dan een derde (35.7%) van deze potentiële kandidaten echter 
geen contact met hun huisarts en bijna de helft (46.7%) van de patiënten die 
wel contact met hun huisarts hadden, werden niet met een NSAID behandeld. 
Dit was belangrijk omdat de potentiële participanten alleen gerecruteerd 
konden worden op het moment dat ze tijdens een reguliere huisartsbezoek 
een NSAID behandeling kregen voor artrose. Het kwam ook vaak voor 
dat deze artrose patiënten wel een NSAID behandeling kregen maar voor 
een andere indicatie dan artrose, of ze kregen een herhaal recept via een 
telefonisch contact met de huisarts(assistent). In totaal waren 170 patiënten 
geschikt voor inclusie waarvan 20 zijn gerekruteerd voor de studie. De meeste 
geschikte patiënten (88.3%) werden niet gerekruteerd vanwege praktijk 
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gerelateerde issues (zoals drukte van de huisarts of vervangend huisarts die 
de behandeling voorschreef) en patiënten gerelateerde issues (zoals exclusie 
criteria of weigering om mee te doen, of uitsluiting door de huisarts).
Uit de interviews met de deelnemende huisartsen bleek dat de meeste huisartsen 
enthousiast waren over de methodologie. Vooral de geautomatiseerde 
procedures vonden de meeste huisartsen aantrekkelijk. Als zwak punt van 
de RDS methodologie werd de rekruteringsstrategie genoemd. Dit vooral 
omdat de rekrutering gedurende normale visites moest plaats vinden en dit 
verstoorde de workfl ow van de praktijk. 
Het EMD blijkt ook een goed instrument te zijn om data over prescripties en 
uitkomsten te verzamelen, met als kanttekening dat de studie-uitkomst moet 
leiden tot huisarts bezoek. Het EMD was bijvoorbeeld niet altijd compleet als 
het ging om de rede van stoppen met de medicatie.
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